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ABSTRACT OF THE DISSERTATION
Genetic risk factors for neurodevelopmental disorders: insights from hiPSC-cerebral
organoids
by
Michelle L. Wegscheid
Doctor of Philosophy in Biology and Biomedical Sciences
Neurosciences
Washington University in St. Louis, 2022
Professor David H. Gutmann, Chair
Professor Aaron DiAntonio, Co-Chair
Neurofibromatosis type 1 (NF1) is a common neurodevelopmental disorder (NDD) characterized
by remarkable phenotypic variability, where affected children manifest a spectrum of central
nervous system (CNS) abnormalities, including brain tumors, impairments in attention, behavior,
learning disabilities, and an increased incidence of autism spectrum disorder (ASD). A
significant barrier to the implementation of precision medicine strategies for children with NF1
is a lack of prognostic risk factors to guide clinical management. However, emerging populationbased genotype-phenotype association studies have suggested that the germline NF1 gene
mutation may represent one clinically actionable risk factor for NF1-associated
neurodevelopmental abnormalities. As a critical step in interpreting the significance of these
reported genotype-phenotype correlations, we sought to determine whether germline NF1 gene
mutations differentially affected human brain development, while controlling for other important
confounding factors (e.g., sex, genomic differences). For these studies, we generated an isogenic
series of CRISPR/Cas9-engineered human induced pluripotent stem cells (hiPSCs) harboring
x

seven different intragenic NF1 patient germline NF1 gene mutations. Using this experimental
platform, we established 2D neural progenitor cell (NPC) and astrocyte cultures, as well as threedimensional (3D) human cerebral organoids (hCOs). While all mutations similarly increased
proliferation and RAS activity in 2D NPCs and astrocytes, we observed striking differences
between NF1 mutations on 2D NPC dopamine levels and 3D NPC proliferation, apoptosis, and
neuronal differentiation in developing hCOs. Importantly, identical abnormalities were observed
using patient-derived hiPSC 2D and 3D cultures bearing the same NF1 gene mutations, thus
establishing differential effects of the germline NF1 gene mutation on human brain development.
Based on these findings, we next sought to determine the cellular and molecular etiologies that
underlie the severe developmental delays and intellectual disability (IQ < 70) seen in children
with a specific type of NF1 mutation involving heterozygous deletion of the NF1 gene and
several contiguous genes (NF1-total gene deletion [NF1-TGD]). Using hCOs from three NF1
patients harboring NF1-TGDs, we identified both neural stem cell (NSC) proliferation and
neuronal maturation abnormalities in NF1-TGD hCOs. While increased NSC proliferation
resulted from decreased NF1/RAS regulation, the neuronal differentiation, survival, and
maturation defects were caused by reduced cytokine receptor-like factor 3 (CRLF3) expression
and impaired RhoA signaling. Furthermore, we demonstrated a higher autistic trait burden in
NF1 patients harboring a deleterious germline mutation in the CRLF3 gene (c.1166T>C,
p.Leu389Pro). Taken together, this body of work conceptually advances the field by (1)
demonstrating differential effects of NF1 mutations at the cellular and tissue levels in humans,
establishing that the germline NF1 gene mutation is one important factor that underlies clinical
variability in this monogenic syndrome, and (2) revealing a new causative gene within the NF1TGD locus responsible for hCO neuronal abnormalities and autism in children with NF1.
xi

Chapter 1: Introduction & Perspective
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1.1 Preface

Parts of this chapter are adapted from the following manuscript:
Wegscheid, M.L., Anastasaki, C. & Gutmann, D.H. Human stem cell modeling in
neurofibromatosis type 1 (NF1). Experimental Neurology 299, 270-280 (2018).

Author contributions for the citation above:
M.L.W. and D.H.G. wrote the paper. M.L.W. and C.A. made the figures.
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1.2 Barriers to precision medicine
Precision medicine is an emerging healthcare strategy with profound potential to improve disease
prevention, management, and treatment for patients. In contrast to the paradigm of care
standardization, in which the same intervention is administered to all patients with a given
condition based on disease-specific guidelines (also known as a “one size fits all” approach), a
precision medicine approach is one in which disease prevention, prognostic predictions,
management strategies and treatment options are precisely and accurately informed by a series of
factors (e.g., genes, epigenetic modifications, environmental influences) for each patient (Figure
1.1). As such, precision medicine is heavily reliant on the identification of key determinants that
account for variability in pathophysiology, clinical presentation, and response to treatment
among individuals with the same disease. An incomplete understanding of the factors underlying
disease variability is one of the most significant barriers to the actualization of precision
medicine for patients.

Figure 1.1 | Precision medicine. Precision medicine leverages patient-specific parameters
(e.g., genes, epigenome, environmental influences) to design and deliver the most
appropriate intervention strategy for each patient, thereby optimizing patient benefit.
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1.3 Clinical heterogeneity in Neurofibromatosis type 1
(NF1)
This challenge is exemplified by Neurofibromatosis type 1 (NF1), a common, monogenic
neurodevelopmental disorder characterized by extreme phenotypic variability. While all
individuals with NF1 harbor a single mutation in one copy of the NF1 gene located on
chromosome 17q11.2 (Uusitalo et al., 2014), patients present with a wide range of clinical
manifestations, including pigmentary abnormalities (café-au-lait macules, skinfold freckling,
Lisch nodules), peripheral (neurofibromas, malignant peripheral nerve sheath tumors) and central
(optic pathway and brainstem gliomas) nervous system tumors, bone abnormalities, vasculopathy
and other cancers (Jett and Friedman, 2010). In addition to these medical problems, as many as
80% of children with NF1 manifest cognitive abnormalities related to learning disabilities (60%)
(Hyman et al., 2006), motor delays (50%) (Soucy et al., 2015), social perception deficits (autism
spectrum disorder; 15-30%) (Morris et al., 2016a), attention deficits (60%) (Hyman et al., 2005),
and, in some cases, severe intellectual disability (Venturin et al., 2004). While there has been
enormous progress since the identification of the NF1 gene in 1990, it is still not possible to
identify those children who are most likely to develop specific medical problems, to predict the
clinical course of their disease, or to anticipate their responses to rationally chosen medical
treatments.

4

1.4 Germline NF1 gene mutations
One of many potential factors underlying the immense clinical heterogeneity in NF1 could be
the specific NF1 germline gene mutation that an individual is born with. Over 1,000 different
pathogenic intragenic variants (e.g., frameshift, missense, nonsense, splice site) throughout the
NF1 gene have been reported in this patient population (ClinVar, Gene ID: 4763, coding
sequence length: 8,520 nucleotides). This large number of mutations, coupled with the lack of
spatial clustering, has led to the widely accepted assumption that all mutations are functionally
equivalent and have no bearing on clinical expression. However, this notion has been
challenged by several population-based studies, which demonstrated differences in the effects of
germline NF1 gene mutations on clinical symptomatology. For instance, patients harboring the
c.2970-2971_delAAT, c.5425C>T and c.3112A>G NF1 germline mutations do not develop
dermal and plexiform neurofibromas, the signature peripheral nervous system tumors in NF1
(Pinna et al., 2015; Trevisson et al., 2019; Upadhyaya et al., 2007). Conversely, children with
large NF1 locus microdeletions and missense mutations involving amino acids 844-848 exhibit
more severe clinical manifestations (Koczkowska et al., 2018b; Mautner et al., 2010). A strong
intra-familial concordance in autism spectrum symptomatology between family members
sharing the same NF1 gene mutation has been reported (Morris et al., 2016a), implicating the
NF1 gene mutation as an important factor in determining NF1-associated autism spectrum
disorder (ASD). In addition, children with NF1-associated optic pathway gliomas were more
likely to harbor 5’ NF1 gene mutations (Anastasaki et al., 2017; Sharif et al., 2011), while
individuals with 3’ NF1 gene mutations had increased autistic trait burden (Morris and
Gutmann, 2018).
5

1.5 Personalized preclinical models
While these correlations underscore the potential importance of the germline mutation as a
predictive risk factor for NF1-associated symptomatology, they do not establish differential
effects of NF1 mutations at the molecular, cellular and tissue levels. Until recently, NF1
preclinical models exclusively employed knockout strategies, either by engineering a single
“knockout” allele (neomycin cassette insertion into the RAS-GAP domain) or conditionally
inactivating the Nf1 gene using Cre-Lox recombination. As these mutations are not
representative of the mutations found in patients with NF1, increasing efforts are being made to
employ personalized murine models harboring patient specific Nf1 gene mutations (Guo et al.,
2019; Li et al., 2016; Toonen et al., 2016). In these early phase studies, germline Nf1 gene
mutations differentially dictated optic glioma (Toonen et al., 2016) and neurofibroma (Li et al.,
2016) formation, and had different effects on NF1 protein (neurofibromin) expression
(Anastasaki et al., 2015).

Authenticated preclinical animal models are valuable experimental platforms to define the
factors that underlie NF1-associated disease pathogenesis and progression. However, it will be
critical to complement these models with preclinical platforms using human cells and tissues.
While rodents and humans share substantial genomic homology (an average of 85% sequence
conservation for protein-coding genes) (Makalowski et al., 1996), there are inherent speciesspecific differences to consider when using animal models to inform about human disorders.
Anatomically, rodent brains are unlike human brains in that they are lissencephalic, meaning that
their cerebral cortices do not undergo gyrification during development like their human
6

counterparts (Semple et al., 2013). In addition, cerebral progenitor zone complexity and
organization differs between rodents and humans (Molnar et al., 2011). Furthermore, specific
cell types, like microglia, exhibit striking interspecies differences in proliferation, immune
system receptor expression and response to immune stimuli in vitro (Smith and Dragunow,
2014).

For these reasons, it would be desirable to complement studies using personalized preclinical
mouse models with human biospecimens. Unfortunately, for CNS clinical phenotypes, human
brain biospecimens are exceedingly rare. Optic pathway gliomas (OPGs) in children with NF1
are almost never biopsied as part of routine medical care (Jett and Friedman, 2010). On the rare
occasion that these tumors are biopsied, patient-derived xenografts (PDX), in which patient
tumor tissues are implanted into immunodeficient mice, could allow for preservation of tumor
histology, genetic composition, and drug sensitivity. This platform has been highly successful for
high-grade brain tumors, such as glioblastoma (Joo et al., 2013), but has been problematic for
low-grade gliomas due to premature senescence and low clonogenic frequencies. Another
approach employs pathologic specimens, which maintain intact tissue architecture and gene
expression patterns. However, the dynamic changes inherent in these tissues are reduced to a
static image, and much of the information in these biospecimens regarding cell-cell interactions,
stromal contributions, or the impact of germline genetics on disease development and
progression is lost.

7

1.6 Human induced pluripotent stem cells (hiPSCs)
These limitations support the use of an in vitro human system amenable to genetic engineering,
as well as dynamic molecular and functional analyses. The discovery of somatic cell
reprogramming to a pluripotent state by Shinya Takahashi and colleagues in 2006 (Takahashi
and Yamanaka, 2006) ushered in an era of in vitro human disease modeling. The work that Dr.
Yamanaka received the Nobel Prize for in 2012 involved retroviral delivery of transcription
factors Oct3/4, Sox2, c-Myc and Klf4 into mouse embryonic fibroblasts, generating induced
pluripotent stem cells (iPSCs) with the capacity to differentiate into any cell type in the body
(Takahashi and Yamanaka, 2006). Over the last ten years, refinements in reprogramming and
differentiation techniques have resulted in the generation and application of human-derived
iPSCs (hiPSCs) (Takahashi et al., 2007) to model complex genetic disorders, such as Rett
syndrome (Marchetto et al., 2010), Fragile X syndrome (Mor-Shaked and Eiges, 2016),
schizophrenia (Brennand et al., 2011), and bipolar disorder (Chen et al., 2014). The ability to
engineer hiPSCs with patient-specific mutations and differentiate them into virtually any cell
type renders the hiPSC platform a powerful technology to dissect the contributions of germline
genetics to disease pathogenesis in NF1 (Figure 1.2).
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Figure 1.2 | hiPSCs for disease modeling in NF1. hiPSCs can be efficiently differentiated
into cell types affected in NF1 using appropriate growth factors, cytokines, and extracellular
matrix molecules.

1.7 Human iPSC-derived cerebral organoids (hCOs)
Cultures of homogenous human-derived cell populations are extremely useful for evaluating
cell-specific molecular signaling pathways in disease, but these two-dimensional (2D) cultures
do not permit a detailed examination of heterogeneous cell-cell interactions, patterning, and
circuit abnormalities seen in the brains of patients with neurodevelopmental disorders. For this
reason, three-dimensional (3D) culture systems have been developed to support the evolution of
9

complex, self-organizing cerebral tissues. These 3D structures, termed human cerebral organoids
(hCOs), can be established from patient-derived iPSCs, and replicate many aspects of the cellular
diversity, connectivity, and regional identity found in the developing human brain (Huch and
Koo, 2015; Lancaster and Knoblich, 2014; Quadrato et al., 2016).

The first cerebral organoids were generated to model microcephaly (Lancaster et al., 2013),
where skin fibroblasts from a patient with truncating CDK5RAP2 mutations were reprogrammed
using lentiviral OCT4, SOX2, MYC and KLF4 delivery. Reverse transcriptase PCR (RT-PCR)
and immunohistochemistry confirmed the presence of cell types from discrete brain regions,
including midbrain, hindbrain, forebrain and hippocampal structures within the tissues, as well as
the sophisticated organization of dorsal cortical regions. Moreover, the organoids derived from
these patient iPSCs had premature neural differentiation and failure of radial glial stem cell
expansion, demonstrating their ability to serve as an in vitro model of a human
neurodevelopmental disorder which had been difficult to recapitulate in mice (Lancaster et al.,
2013). Cerebral organoids have since been leveraged as experimentally tractable platforms to
study the mechanisms underlying several other neurodevelopmental disorders (e.g., ASD,
lissencephaly, Zika virus-induced microcephaly) (Bershteyn et al., 2017; Mariani et al., 2015;
Qian et al., 2016a). Based on these successes, 3D cerebral organoid cultures represent a
promising platform for dissecting the complex interplay between different cell types relevant to
disease pathogenesis and progression for specific NF1 clinical features.

10

1.8 Directions
In this introduction, we highlight the pressing need to identify key determinants underlying
disease variability as a critical step towards actualizing precision medicine. This challenge is
exemplified by NF1, a monogenic disorder characterized by immense clinical heterogeneity.
Based on emerging genotype-phenotype association studies in NF1, we hypothesized that
the germline NF1 gene mutation may represent one clinically actionable risk factor for
NF1-associated symptomatology. The studies described in this dissertation aim to critically
evaluate this hypothesis. For these studies, we generated a collection of isogenic and patientderived hiPSCs harboring NF1 patient NF1 gene mutations. Leveraging this hiPSC resource, we
pioneered an hiPSC-derived cerebral organoid platform (Figure 1.3) to investigate the effects of
different NF1 mutations on human brain development.

11

Figure 1.3 | Cerebral organoid cultures. hiPSCs are aggregated to allow for deposition of
matrix and the formation of embryoid bodies. The generation of cerebral organoids involves
neural induction in stationary culture. After expansion of the resulting neuroepithelium,
samples are transferred to a rotating suspension culture to promote nutrient diffusion and
further organoid maturation. hCOs are subsequently collected for molecular and cellular
analyses. Representative hCOs generate PAX6+ neural progenitor cells (NPCs), GFAP+
astrocytes, and NeuroD1+ neurons. Scale bars: 50 µm.

First, we analyzed an isogenic series of CRISPR/Cas9-engineered hiPSCs harboring seven
different intragenic NF1 patient germline NF1 gene mutations, as well as patient-derived hiPSCs
bearing the same mutations (Figure 1.4). Importantly, unlike prior studies, the use of an isogenic
series of hiPSCs eliminates other contributing factors, like sex and genomic variation (potential
modifier genes) and permits a direct examination of the effects of different NF1 gene mutations.
We evaluated the effects of these different NF1 gene mutations on hiPSC-derived 2D neural

12

progenitor cell (NPC) and astrocyte cultures, as well as 3D hCOs. This analysis is depicted in
Chapter 2.

Second, we sought to understand the molecular and cellular etiologies underlying severe
developmental delays and intellectual disability seen in children with a microdeletion on
chromosome 17q11.2, involving the NF1 gene and flanking regions (1.4 Mb NF1-total gene
deletion; NF1-TGD). For these studies, we analyzed hCOs derived from three neurologically
normal control individuals and three individuals harboring a 1.4 Mb NF1-TGD. The results of
experiments leveraging 17q11.2 microdeletion hCOs harboring a total heterozygous NF1 gene
deletion are instructive for interpreting findings in hCOs harboring intragenic NF1 mutations, as
well as in the identification other important genes contained within the NF1-TGD locus that
could contribute to specific clinical phenotypes. This analysis is depicted in Chapter 3.

Figure 1.4 | Schematic diagram showing the chromosomal region 17q11.2. The NF1 gene
containing seven engineered NF1 patient NF1 gene mutations is indicated in red. The
location of the RAS-GAP domain is highlighted in black.
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Chapter 2: Isogenic hiPSC-derived CNS cells
and hCOs establish differential effects of NF1
gene mutations

14

2.1 Preface

This chapter is adapted from the following manuscript:
Anastasaki, C.*, Wegscheid, M.L.*, et al. Human iPSC-derived Neurons and Cerebral
Organoids Establish Differential Effects of NF1 Gene Mutations. Stem Cell Reports 14, 541-550
(2020). *co-first authors

Author contributions for the citation above:
C.A., M.L.W., and D.H.G. designed and analyzed the experiments. C.A., M.L.W., K.H., J.B.P.,
N.D.K., J.C., O.C., and J.D.D. conducted and/or interpreted the experiments. The manuscript
was assembled by C.A., M.L.W. and D.H.G.
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2.2 Abstract
Neurofibromatosis type 1 (NF1) is a common neurodevelopmental disorder caused by a
spectrum of distinct germline NF1 gene mutations, traditionally viewed as equivalent loss-offunction alleles. To specifically address the issue of mutational equivalency in a disease with
considerable clinical heterogeneity, we engineered seven isogenic human induced pluripotent
stem cell lines, each with a different NF1 patient NF1 mutation, to identify potential differential
effects of NF1 mutations on human central nervous system cells and tissues. While all mutations
increased proliferation and RAS activity in two-dimensional (2D) neural progenitor cells (NPCs)
and astrocytes, we observed striking differences between NF1 mutations on 2D NPC dopamine
levels, and 3D NPC proliferation, apoptosis, and neuronal differentiation in developing cerebral
organoids. Together, these findings demonstrate differential effects of NF1 gene mutations at the
cellular and tissue levels, suggesting that the germline NF1 gene mutation is one factor that
underlies clinical variability.

2.3 Introduction
Cognitive impairments in individuals with NF1 are characterized by extensive variability,
ranging from brain tumors and motor delays to learning difficulties, attention deficits and autism
(Fisher et al., 2018; Hyman et al., 2006; Jett and Friedman, 2010; Korf, 2013; Morris and
Gutmann, 2018). One of many potential factors underlying this clinical variability could be the
specific NF1 germline mutation, a notion suggested by population-based studies (Anastasaki et
al., 2017; Bolcekova et al., 2013; Kehrer-Sawatzki et al., 2017; Koczkowska et al., 2018a; Pinna
16

et al., 2015; Rojnueangnit et al., 2015; Sharif et al., 2011; Trevisson et al., 2019; Upadhyaya et
al., 2007). For example, patients harboring the c.2970-2971_delAAT, c.5425C>T and
c.3112A>G NF1 germline mutations lack dermal and plexiform neurofibromas, the signature
peripheral nervous system tumors in NF1 (Pinna et al., 2015; Trevisson et al., 2019; Upadhyaya
et al., 2007).

While these studies raise the possibility that not all NF1 gene mutations are functionally
equivalent, they do not establish differential effects of NF1 patient germline mutations at the
cellular or tissue levels, a critical step in interpreting the significance of reported genotypephenotype associations. To specifically evaluate differential NF1 mutation effects on human
CNS cells and tissues, while controlling for important confounding factors (e.g., sex, genomic
differences), we generated an isogenic series of human induced pluripotent stem cells (hiPSCs)
harboring seven representative NF1-patient NF1 mutations.

2.4 Materials and methods
Human iPSCs, hiPSC-derived CNS cells and hCOs
Seven distinct NF1-patient germline NF1 gene mutations (Transcript ID NM_000267;
c.1149C>A, c.1185+1G>A, c.2041C>T, c.3431-32_dupGT, c.5425C>T, c.6513T>A,
c.6619C>T) were individually engineered using CRISPR/Cas9 technology into a single
commercially available male control human iPSC line (BJFF.6) by the Washington University
Genome Engineering and iPSC Core Facility (GEiC). Heterozygous mutations were confirmed
by next-generation sequencing (NGS) sequencing (Bell et al., 2014), and two different clones
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were expanded for each of the six NF1-mutant and the control lines (Figure 2.1A-C). Only a
single clone heterozygous for the c.6619C>T NF1 mutation could be generated without any
additional genomic insertions or deletions. Retention of heterozygosity in the hiPSCs was
confirmed by sequencing after five passages, as well as in all derivative cell lines by RAS
activity assays. Similar results were obtained after each passage. Additionally, iPSCs
reprogrammed from the fibroblasts of three NF1 patients (c.1185+1G>A; c.5425C>T;
c.6513T>A) and one control subject (Anastasaki et al., 2015) were employed for subsequent
analyses. For NPC differentiation, hiPSCs were passaged onto PLO/Laminin (Millipore Sigma)coated plates using ReLeSR (STEMCELL Technologies) and seeded at 200,000 cells/cm2 in
NPC induction medium (50% DMEM F12 [Gibco], 50% Neurobasal medium [Gibco],
supplemented with N2, B27 [Fisher], 2mM GlutaMax [Gibco], 10ng/mL hLIF, 4µM
CHIR99021, 3µM SB431541, and 0.1µM Compound E [all from STEMCELL Technologies]).
Cells were maintained in this medium supplemented with 2µM Dorsomorphin for 3 days and
without Dorsomorphin (STEMCELL technologies) for an additional 5 days. NPCs were
subsequently incubated in NPC maturation medium (50% DMEM/F12, 50% Neurobasal medium
supplemented with N2, B27, 2mM GlutaMax, 10ng/mL hLIF, 3µM CHIR99021 and 2µM
SB431541), and were passaged weekly following Accutase (STEMCELL Technologies)
dissociation according to manufacturer’s instructions. NPCs were treated for 24 hours with
10µg/µL fibroblast growth factor (FGF) or brain-derived neurotrophic factor (BDNF; both
STEMCELL Technologies) to assess growth factor-induced cell proliferation. GABAergic
neurons were differentiated as previously described (Liu et al., 2013). For astrocytic
differentiation, NPCs were plated on Primaria-coated plates in Astrocyte Growth Media
(ScienCell) for a minimum of two weeks and a maximum of ten passages (Tcw et al., 2017).
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Cerebral organoids were generated as previously described (Lancaster and Knoblich, 2014) with
modifications: Embryoid bodies (EBs) were cultured in NIM (STEMCELL Technologies)
supplemented with 20μM Rock inhibitor Y27632 (Millipore) and 4ng/mL bFGF (Peprotech) for
the first 5 days, followed by NIM alone for an additional 4 days prior to direct transfer to
cerebral organoid media without Matrigel embedding. Cerebral organoids were maintained for
up to 56DIV. All experiments employed at least three biological replicates from two
independently generated hiPSC clones.

RNA extraction, cDNA production, qPCR and targeted allele expression analysis
Total RNA was extracted from snap-frozen cell pellets of three independent passages of two
clones per hiPSC line, using QIAGEN RNeasy Mini Kit. Total RNA was reverse-transcribed
into cDNA using Applied Biosystems High-Capacity cDNA Reverse Transcription Kit per the
manufacturer’s instructions. Real-time quantitative PCR (qPCR) was performed using TaqMan
Gene Expression assays NF1 (Hs01035108_m1) and GAPDH (Hs02786624_g1; internal
control), and relative NF1 expression was calculated using the ΔΔCT analysis method following
manufacturer’s instructions (ThermoFisher). For allele-specific expression analyses, primer pairs
including Illumina adapter sequences concatenated to their 5’ ends were used for all NF1-mutant
hiPSCs to initially amplify the mutation-surrounding region, and later to add the P5 sites, P7
sites, and sample-specific index. The samples were pooled and the amplicons were deepsequenced on a MiSeq machine. Illumina adapters, 5’and 3’ bases with quality scores <25, as
well as sequences <25 bases long were trimmed using the Trimmomatic v0.331 software.
Trimmed reads were aligned to the human reference genome hg19 using STARv2.52 software
and allele reads were calculated using Integrative Genomics Viewer v2.3.293.
19

Allele-Specific Analysis Primers Used
The primers used for the first PCR reaction including the Illumina adaptor sequences were the
following:
1149C>A FW:
GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCTCTACTTGTTCAGTCCATGGTGG
1149C>A REV:
ACACTCTTTCCCTACACGACGCTCTTCCGATCTCCAATGCGGAATTGGTGATGA
2041C>T FW:
GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCTAATTACTACGTACTCCTGGAGC
2041C>T REV:
ACACTCTTTCCCTACACGACGCTCTTCCGATCTGCAAGAGGTTATGCACTGAC
3431-32_dupGT FW:
GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCTGACTGCAGTGAAGTTGA AGATG
3431-32_dupGT REV:
ACACTCTTTCCCTACACGACGCTCTTCCGATCTGTAGCTCTTGTCTGGAGAT CC
5425C>T FW:
GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCTGAAGCCATTGTCCAGTCTATC
5425C>T REV:
ACACTCTTTCCCTACACGACGCTCTTCCGATCTGGTACAAGTTAAGGCACACAG
6513T>A FW:
GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCTGACTCAGTCTGACAGAGTTCTC
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6513T>A REV:
ACACTCTTTCCCTACACGACGCTCTTCCGATCTCTAGTTCTGTCCACTGGTCC
6619C>T FW:
GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCTTGCCTTCCGTTCCAGTTACC
6619C>T REV:
ACACTCTTTCCCTACACGACGCTCTTCCGATCTGAGCTCTTGGTTGCAGGGAT
The primers used for the second amplification PCR reaction which include the unique indexes
employed to identify different sequencing products were the following:
Primer 1.0 FW:
AATGATACGGCGACCACCGAGATCTACACACACTCTTTCCCTACACGACGCTCTTC
CGATCT
Primer 1.0 SIC2 FW:
AATGATACGGCGACCACCGAGATCTACACAATGAAACACTCTTTCCCTACA
CGACGCTCTTCCGATCT
Common REV: GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCT
Index 1 REV: CAAGCAGAAGACGGCATACGAGATAAATAGATGGTGACTGGAGTTC
Index 2 REV: CAAGCAGAAGACGGCATACGAGATCAGAGGAGAGTGACTGGAGTTC
Index 3 REV: CAAGCAGAAGACGGCATACGAGATCGTATAGATGTGACTGGAGTTC
Index 4 REV: CAAGCAGAAGACGGCATACGAGATAAGGGCTCAGTGACTGGAGTTC

Immunohistochemistry and ELISA Assays
Immunocytochemistry on NPCs, astrocytes and neurons was performed following established
protocols (Anastasaki et al., 2015) using the antibodies described (Table 2.1). RAS activity
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(ThermoFisher), GABA, dopamine (both Rocky Mountain Diagnostics) detection (Anastasaki et
al., 2015), BrdU proliferation assays (Roche) and direct cell counting were performed as
previously described (Toonen et al., 2016). Immunohistochemistry on cryosections of cerebral
organoids was performed as previously described (Sloan et al., 2018). A minimum of three
independent samples representing different passages of two separate clones were employed for
each line.

Mice
All animals were maintained on an inbred C57BL/6 background using a 12 h light–dark cycle
with ad libitum access to food and water. Heterozygous Nf1 mice were generated to harbor point
mutations corresponding to the human c.1149C>A, c.2041C>T, c.3431_32dupGT and
c.5425C>T mutations. The c.1149C>A, c.2041C>T, and c.3431_32dupGT mice were generated
using C57BL/6 ES cells backcrossed a minimum of 10 times to wild-type C57BL/6 mice, while
the c.5425C>T mice were generated by CRISPR/Cas9 engineering on a C57BL/6 genetic
background and heterozygous mutation was confirmed by direct sequencing.

Statistics
All statistical tests were performed using GraphPad Prism 5 software. T-tests, one-way or twoway analysis of variance (ANOVA) with Dunnett or Bonferroni post-test correction was
performed using GraphPad Prism 5 software. Statistical significance was set at P < 0.05.
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Next Generation RNA Sequencing and Analysis
RNA was extracted from three independently generated samples of isogenic CTL or NF1-mutant
(c.1185+1G>A; c.6513T>A) NPCs, and one sample each from the non-isogenic CTL and
patient-derived NF1-mutant NPCs harboring the same NF1 mutations. Samples were prepared
according to library kit manufacturer’s protocol, indexed, pooled, and sequenced on an Illumina
HiSeq. Basecalls and demultiplexing were performed with Illumina’s bcl2fastq software and a
custom python demultiplexing program with a maximum of one mismatch in the indexing read.
RNA-seq reads were then aligned to the Ensembl release 76 primary assembly with STAR
version 2.5.1a. Gene counts were derived from the number of uniquely aligned unambiguous
reads by Subread:featureCount version 1.4.6-p5. Isoform expressions of known Ensembl
transcripts were estimated with Salmon version 0.8.2. Sequencing performance was assessed for
the total number of aligned reads, total number of uniquely aligned reads, and features detected.
The ribosomal fraction, known junction saturation, and read distribution over known gene
models were quantified with RSeQC version 2.6.2. The raw gene count matrix was then
imported into Partek Flow software, version 8.0. Normalization size factors were calculated for
all gene counts by CPM to adjust for differences in sequencing depth. Ribosomal genes and
genes not expressed in the smallest group size minus samples greater than one count-per-million
were excluded from further analysis. Gene-specific analysis was then performed using the
lognormal with shrinkage model (limma-trend method) to analyze for differential expression
between the three groups of samples. Principle component analysis (PCA) was conducted in
Partek Flow using normalized gene counts. The "grouping" is simply a post hoc highlighting of
the genotypes for assistance in visualizing that the different samples clustered together by
genotype during the principle component. For further visualization, a heatmap was generated
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using the differential genes for each group filtered at p-values ≤ 0.05 and log fold-changes more
extreme or equal to ±2. Features and samples were clustered using Pearson Correlation as a
distance metric. The accession number for the deep sequencing data reported in this paper is
GEO: GSE144601.

2.5 Results
Generation of isogenic NF1-mutant hiPSCs
The seven NF1 pathogenic mutations, derived from patients in our clinical population at
Washington University/ St. Louis Children’s Hospital, represent the spectrum of mutations
typically seen in individuals with NF1. In this regard, the selected mutations were interspersed
throughout the NF1 protein (neurofibromin) coding sequence, were both proximal and distal to
the well-characterized RAS GTPase activating protein (RAS-GAP) domain (GRD), and included
four nonsense (c.1149C>A, c.2041C>T, c.6513T>A, c.6619C>T), one splice site
(c.1185+1G>A), one missense (c.5425C>T) and one frameshift (c.3431-32_dupGT) mutation
(Figure 2.1, 2.2, 2.3A). All the engineered isogenic hiPSCs harbored only a single NF1 mutation
(“NF1-mutant”), retained expression of the remaining wild-type NF1 allele as confirmed by
DNA and RNA sequencing (Figure 2.1D), and expressed similar levels of NF1 mRNA (Figure
2.3B). For all hiPSC lines with two clones, identical results were obtained using numerous
independently generated biological replicates, as well as with three NF1 patient-derived hiPSC
lines generated from somatic cells (fibroblasts; Figure 2.4, Table 2.2).
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Isogenic NF1-mutant hiPSC-derived NPCs and astroglia have increased RAS activity and
proliferation
To determine the consequences of the different NF1 gene mutations on neurofibromin signal
transduction and function in human CNS cells, NF1-mutant and control hiPSCs were first
differentiated into neural progenitor cells (NPCs) capable of generating both neurons (TUJ1+
cells) and glia (S100+ cells) (Figure 2.2). Since neurofibromin primarily functions as a RASGAP to control cell proliferation, we initially assessed RAS activity. Consistent with this
negative RAS regulatory property, all NF1-mutant NPCs exhibited a comparable 1.8-2.2-fold
increase in RAS-GTP relative to the isogenic control (Figure 2.3C). Importantly, the addition of
growth factors (FGF or BDNF) did not further increase RAS activity in the NF1-mutant lines but
resulted in greater RAS-GTP levels in the control lines, equivalent to the levels observed in the
unstimulated NF1-mutant lines (Figure 2.3D-E). These findings demonstrate that a heterozygous
NF1 mutation phenocopies the effect of exogenous growth factor stimulation on RAS activation.
Additionally, all NF1-mutant NPCs exhibited increased cell division, as evidenced by elevated
BrdU incorporation (2.6-3.2-fold increase; Figure 2.3F) and total cell number (1.9-2-fold
increase; Figure 2.3G). To evaluate the effects of distinct NF1 gene mutations on the production
of NPCs in a three-dimensional (3D) model of human brain development, we generated cerebral
organoids from the control and NF1-mutant hiPSC lines. Despite repeated efforts, we were
unable to derive organoids from two of the seven NF1-mutant hiPSC lines (c.2041C>T and
c.6513T>A), but successfully generated organoids from the control and five of the seven NF1mutant hiPSC lines (c.1149C>A, c.1185+1G>A, c.3431-32_dupGT, c.5425C>T, c.6619C>T;
Figure 2.3H). The organoids formed radially organized ventricle-like structures populated by
SOX2+ NPCs by 16 days in vitro (DIV). Similar to the 2D cultures, all NF1-mutant organoids
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exhibited a 2.8-3.2-fold increase in RAS activity (Figure 2.3I), as well as a 1.6-2.2-fold increase
in total NPCs per ventricular zone at 16DIV (Figure 2.3J).

Next, we sought to determine whether these heterozygous NF1 mutational effects were observed
in another proliferating CNS cell type by differentiating the NPCs into astrocytes (Figure 2.5A).
Similar to the NPCs, NF1-mutant astrocytes exhibited 2-2.3-fold elevated RAS activity (Figure
2.5B), 2.3-2.7-fold increased cell division (Figure 2.5C) and 2.1-2.5-fold greater total cell
number (Figure 2.5D) relative to the control line. Consistent with the 2D astrocytes, 56DIV
NF1-mutant organoids had more EAAT1- and GFAP-expressing cells (astrocytes) (Figure 2.5E)
compared to control organoids. Importantly, isogenic NF1-mutant NPCs and organoids were
similar to those of their respective patient-derived NPCs (c.1185+1G>A; c.5425C>T;
c.6513T>A) and organoids (c.1185+1G>A; c.5425C>T) (Figure 2.4, 2.6, Table 2.2) in RAS
activity and NPC proliferation, as well as to whole brain lysates from genetically engineered
mice (GEM) harboring the analogous germline Nf1 gene mutations (c.1149C>A, c.2041C>T,
c.3431-32_dupGT, and c.5425C>T; Figure 2.7A). Taken together, these data illustrate that all
heterozygous NF1 mutations increase RAS activity and RAS-regulated cell proliferation in both
human and murine CNS cells.

hiPSC-derived NF1-mutant neurons exhibit both shared and differential deficits in 2D
cultures
As many children with NF1 exhibit cognitive deficits and neurodevelopmental delays (Hyman et
al., 2006; Hyman et al., 2005; Jett and Friedman, 2010; Morris and Gutmann, 2018), we sought
to determine the effects of distinct NF1 germline mutations on human CNS neuronal function
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and differentiation. Based on the observation that Nf1-mutant (Nf1+/-) mice exhibit elevated
GABA-ergic tone that contributes to the observed deficits in learning and spatial memory (Costa
et al., 2002; Cui et al., 2008), we assayed GABA levels in NPC-derived GABAergic neurons
(Figure 2.7B, 2.4E). In all NF1-mutant neurons (2D cultures), GABA levels were increased
(6.5-7.8-fold) relative to isogenic control neurons, revealing a shared abnormality in all NF1mutant GABAergic neurons.

In contrast, NF1-mutant NPCs in 2D cultures displayed striking differences in dopamine (DA;
Figure 2.7C) levels. DA levels were reduced by >70% in the c.1149C>A, c.2041C>T and
c.6619C>T NF1 mutants, but by <40% in the c.1185+1G>A, c.3431-32_dupGT, c.5425C>T and
c.6513T>A NF1 mutants relative to the control line. These differential effects mirror findings
using patient-derived NPCs (Figure 2.4F, Table 2.2) (Anastasaki et al., 2015), as well as mice
engineered with NF1 patient-specific Nf1 germline mutations (Figure 2.7D) (Toonen et al.,
2016). Taken together, these findings demonstrate the existence of differential effects of NF1
germline mutations on neuronal differentiation in vitro.

Differential effects of NF1 mutations on cerebral organoid NPC proliferation, apoptosis,
and differentiation
To further explore the differential effects of NF1 mutations in the developing human brain, we
used the more contextually relevant cerebral organoid platform (see Section 2.4: Methods and
Materials). Examination of NPC proliferation, apoptosis, and neuronal differentiation in 16DIV
cerebral organoids revealed two distinct groups of NF1 mutants (Figure 2.8): Group 1
(c.1185+1G>A; c.5425C>T; c.6619C>T) NF1 mutants exhibited increased NPC proliferation
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(1.3-1.4-fold) and apoptosis (2-3-fold), but had similar numbers of early (NeuroD1+, TUJ1+) and
late (MAP2+) immature neurons relative to controls. In this manner, Group 1 NF1 mutations
increased both proliferation and apoptosis during NPC differentiation, allowing neurogenesis to
proceed normally. In contrast, Group 2 (c.1149C>A; c.3431-32_dupGT) NF1-mutant organoids
had normal NPC proliferation, but reduced NPC apoptosis (70-92% reduction) and very few
immature neurons relative to the isogenic controls (73-84% reduction). In this latter group, the
reduction in NPC death was coupled with a delay in neurogenesis, suggesting that inappropriate
survival of NPC subpopulations creates a barrier to initiating timely neuronal differentiation.
Importantly, these observations persist in patient-derived cerebral organoids harboring the same
mutations (Figure 2.6, Table 2.2).
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2.6 Figures and tables

Figure 2.1 | Isogenic NF1-mutant hiPSC sequencing and allele expression analysis of
isogenic and patient-derived NF1-mutant hiPSCs.
(A) Snapgene view of NGS sequencing of all NF1-mutant hiPSC clones. (Block only: control;
Block/mod: introduced NF1 gene mutation). (B-C) Table and histogram summarizing the
percentage of sequence reads detected for the mutant and reference (wild-type) alleles at the
mutation site at the genomic level. (D) Analysis of reference and mutant (SNP) allele expression
in each NF1-mutant hiPSC line at the RNA level demonstrates that the wild-type reference allele
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is over-represented in all NF1-mutant hiPSCs relative to the mutation-bearing (SNP) allele. Data
are represented as the percentages of reference and mutant reads relative to the total reads.
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Figure 2.2 | Analysis of isogenic hiPSCs, NPCs, and cerebral organoids.
(A) Immunofluorescence analysis of all hiPSCs with the NANOG, SOX2, OCT4A, SSEA-4,
TRA-1-60, and TRA-1-81 pluripotency markers. Scale bar, 100µm. (B) NPCs were
immunopositive for the SOX2, BLBP and NESTIN neural stem cell markers (top two panels),
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and were multipotent, as illustrated by TUJ1+ and S100β+ double labeling (bottom panel). Scale
bars, 100µm. (C) Control and NF1-mutant NPC-differentiated GABAergic neuronal cultures
were immunopositive for GAD67 (green) and immunonegative for the excitatory neuron marker
glutamate synthetase (GS; red). Scale bar, 100µm.

32

33

Figure 2.3 | Isogenic NF1-mutant hiPSC-derived NPCs exhibit increased RAS activity and
cell proliferation.
(A) Schematic diagram illustrating the position of the engineered NF1 patient mutations within
the NF1 gene. The location of the RAS-GAP domain is highlighted in black. (B) Relative NF1
mRNA expression in isogenic NF1-mutant NPCs is similar to the controls. (C–E) (C)
Quantitation demonstrating increased RAS activity (RAS-GTP) in isogenic NF1-mutant NPCs
relative to controls (CTL) before and after the addition of (D) 10 µg/mL FGF or (E) BDNF. A
minimum of three independent replicates was performed for each treatment condition. (F) BrdU
incorporation is increased by 2.6- to 3.2-fold in NF1-mutant NPCs relative to control NPCs. (G)
1.9- to 2-fold increases in total cell numbers were observed in NF1-mutant NPCs compared with
controls. (H) Representative bright-field images of embryoid bodies and cerebral organoids at 16
and 56DIV. (I-J) (I) Quantitation demonstrating increased RAS activity (2.8- to 3.2-fold) and (J)
increased numbers of SOX2+ NPCs per ventricular zone (1.6- to 2.2-fold) in 16DIV NF1-mutant
cerebral organoids relative to control organoids. Each dot represents an independently generated
data point derived from separate experiments and the two different clones for each line are
denoted as black versus gray dots. All data are represented as means ± SEM. (B, C, F, G, I, and
J) One-way ANOVA with Tukey post-test. (D-E) Two-way ANOVA with Bonferroni post-test.
n.s., not significant. Scale bar, 1 mm.

34

35

Figure 2.4 | Comparisons between isogenic and patient-derived NF1-mutant hiPSC-NPCs.
(A) Relative NF1 mRNA expression, (B) RAS activity, (C) BrdU incorporation, and (D) cell
numbers are similar between the isogenic and their respective patient-derived NPC lines that
harbor the same NF1 gene mutation. The top panels illustrate all the clones (Isogenic clones: I1,
I2; white, grey circles, respectively; Patient-derived clones: P1, P2; orange and blue circles,
respectively) employed for each assay, and represent comparisons between all NF1-mutant NPCs
and controls. The bottom panels illustrate the individual comparisons between the isogenic (I1,
I2) and their respective patient-derived (P1, P2) NPCs (CTL; c.1185+1G>A; c.5425C>T;
c.6513T>A). Relative (E) GABA levels and (F) DA levels are similar between the isogenic and
their respective patient-derived NPC lines harboring the same NF1 gene mutation. The top
panels illustrate all the clones (Isogenic clones: I1, I2; white, grey circles, respectively; Patientderived clones: P1, P2; orange and blue circles, respectively) employed for each assay, and
represent the comparisons between all NF1-mutant NPCs and controls. The bottom panels
illustrate the individual comparisons between the isogenic (I1, I2) and their respective patientderived (P1, P2) NPCs (CTL; c.1185+1G>A; c.5425C>T; c.6513T>A). All data are represented
as means ± SEM; Oneway ANOVA with Tukey post-test. ns, not significant. (G) PCA plot and
(H) histogram analysis illustrate differential clustering of gene expression between patientderived and isogenic NPCs harboring two separate NF1 mutations (c.1185+1G>A; c.6513T>A)
or no NF1 mutation (control; CTL), following next-generation sequencing.
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Figure 2.5 | hiPSC-derived NF1-mutant astroglia exhibit increased RAS activity and cell
proliferation.
(A) NF1-mutant and control NPCs were differentiated into GFAP+, S100+, EAAT1+, and
EAAT2+ astrocytes in 2D cultures. Scale bar, 100 µm. (B) RAS-GTP was increased by 2- to 2.337

fold in NF1-mutant astrocytes relative to controls (CTL). (C) Proliferation of NF1-mutant
astrocytes was 2.3- to 2.7-fold higher relative to controls. (D) Direct cell counting demonstrated
a 2.1- to 2.5-fold increase in NF1-mutant astrocytes compared with controls.
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Figure 2.6 | Comparisons between isogenic and patient-derived NF1-mutant hiPSCorganoids.
Representative images of (A) NPC proliferation (Ki67+ cells; white arrowheads), (B) NPC
apoptosis (cleaved caspase-3; white arrowheads), (C, D) early immature neurons (NeuroD1;
TUJ1; white arrowheads), (E) late immature neurons (MAP2; white arrowheads) at 16DIV, and
the production of (F) EAAT1+ glial cells and (G) GFAP+ fibers at 56DIV in cerebral organoids
generated from c.1185+1G>A and c.5425C>T patient-derived hiPSC lines. Scale bars: (C)
10µm; (A, B, D, E, F, G) 50µm. There were no differences in (H) RAS activity or (I) SOX2+
NPCs per ventricular zone (VZ) between the isogenic NF1-mutant cerebral organoids and their
corresponding patient-derived at 16DIV. There were no differences in (J) %Ki67+ NPCs per VZ,
(K) %cleaved caspase-3+ NPCs per VZ, or (L) NeuroD1+ immature neurons between the
isogenic NF1-mutant and their corresponding patient-derived cerebral organoids at 16DIV. The
top panels illustrate all the clones (Isogenic clones: I1, I2; white, grey circles, respectively;
Patient-derived clones: P1, P2; orange and blue circles, respectively) employed for each assay,
and represent the comparisons between all NF1-mutant organoids and controls. The bottom
panels illustrate the individual comparisons between the isogenic (I1, I2) and their respective
patient-derived (P1, P2) NPCs (c.1185+1G>A; c.5425C>T). All data are represented as means ±
SEM; One-way ANOVA with Tukey post-test. ns, not significant.
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Figure 2.7 | hiPSC-derived NF1-mutant neurons, NPCs, and Nf1-mutant mice display
molecular similarities and differences.
(A) Nf1-mutant (c.1149C > A, c.2041C > T, c.3431- 32_dupGT, c.5425C > T) genetically
engineered mouse brain lysates exhibit increased RAS activity compared with wild-type
littermate controls. (B) GABA levels are increased in all NF1-mutant NPC-derived neurons
relative to controls. (C-D) Dopamine levels are differentially reduced in (C) NF1-mutant NPCs
relative to controls and (D) Nf1-mutant genetically engineered mouse brain lysates compared
with WT littermate controls. Each dot represents an independently generated data point derived
from separate experiments and the two different clones for each line are denoted as black versus
gray dots. All data are represented as means ± SEM. One-way ANOVA with Tukey post-test.
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Figure 2.8 | Differential effects of NF1 mutations on cerebral organoid progenitor cell
dynamics and neurogenesis.
(A-B) SOX2+ NPCs in the ventricular zones of group 1 NF1-mutant cerebral organoids exhibit
(A) 1.3- to 1.4-fold increased proliferation (Ki67+ cells; white arrowheads) and (B) 2- to 3-fold
increased cell apoptosis (cleaved caspase-3; white arrowheads) compared with control and group
2 cerebral organoids at 16DIV. (C–E) Decreased numbers of (C, D) early immature neurons
(NeuroD1; TUJ1 white arrowheads) and (E) late immature neurons (MAP2; white arrowheads)
migrating into the periventricular zone of group 2 compared with group 1 and control cerebral
organoids at 16DIV. (F) Quantifications of %Ki67+ NPCs, %cleaved caspase-3+ NPCs and
NeuroD1+ immature neurons in NF1-mutant cerebral organoids compared with controls at
16DIV. Each dot represents an independently generated data point derived from separate
experiments and the two different clones for each line are denoted as black versus gray dots. All
data are represented as means ± SEM. One-way ANOVA with Dunnett post-test. n.s., not
significant. Scale bars: (C) 10 µm; (A, B, D, and E) 50 µm.
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Table 2.1 | Primary antibodies.
Antibody

Vendor

Catalog No

Host

Application (dilution)

BLBP

Millipore

ABN14

Rabbit

ICC (1:200)

Cleaved caspase-3

Cell Signaling

9664

Rabbit

IF (1:250)

EAAT1

Abcam

ab416

Rabbit

ICC, IF (1:500)

EAAT2

Abcam

ab41621

Rabbit

ICC (1:500)

GFAP

Abcam

ab4648

Mouse

ICC, IF (1:500)

Ki67

Fisher Scientific

BDB556003

Mouse

IF (1:100)

MAP2

Abcam

ab11267

Mouse

IF (1:500)

Nanog (D73G4)

Cell Signaling

9656S

Rabbit

ICC (1:200)

Nestin

Abcam

ab92391

Rabbit

ICC (1:250)

NeuroD1

Abcam

ab60704

Mouse

IF (1:500)

Oct-4A (C30A3)

Cell Signaling

9656S

Rabbit

ICC (1:200)

S100β

Abcam

ab41548

Rabbit

ICC (1:200)

SOX2

Cell Signaling

4900S

Mouse

ICC (1:1000); IF (1:250)

Sox2 (D6D9)

Cell Signaling

9656S

Rabbit

ICC (1:200)

SOX2

Abcam

ab92494

Rabbit

IF (1:250)

SSEA4 (MC813)

Cell Signaling

9656S

Mouse

ICC (1:200)

TRA-1-60 (S)

Cell Signaling

9656S

Mouse

ICC (1:200)

TRA-1-81

Cell Signaling

9656S

Mouse

ICC (1:200)

TUJ-1

Abcam

ab78078

Mouse

ICC (1:1000)
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Table 2.2 | Inter-clone analysis of control and NF1-mutant hiPSC-derived cells and
organoids.

Table detailing the inter-clone analyses of isogenic iPSC-derived NPCs and organoids, as well as
isogenic versus patient-derived hiPSC-derived NPCs and organoids harboring the same germline
NF1 mutations. There are no statistically significant differences in the relative NF1 mRNA
expression in NPCs, RAS activity, BrdU incorporation, or cell number in NPCs or astrocytes,
GABA and dopamine (DA) levels in NPCs, %Ki67+ progenitor cells per ventricular zone (VZ),
RAS activity, NPCs per ventricular zone (VZ), NeuroD1+ cells or %cleaved caspase3+
progenitor cells per VZ in cerebral organoids. *t-test; P-values reported, **One-Way ANOVA; F
/ P-values reported, respectively. n/a: not applicable.
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2.7 Discussion
The findings described in this report, in combination with compelling population-based
genotype-phenotype associations, suggest that the germline NF1 gene mutation is one of the
factors that underlies clinical heterogeneity in patients with NF1. Using an isogenic series of
NF1-mutant hiPSC lines, we identified differential NF1 mutational effects on human CNS cells
and tissues. Importantly, unlike prior studies, the use of an isogenic series of hiPSCs eliminates
other contributing factors, like sex and genomic variation (potential modifier genes) and permits
a direct examination of the effects of different NF1 gene mutations. Moreover, this study raises
several important points relevant to NF1 pathobiology.

First, we established that all heterozygous NF1 gene mutations similarly increase CNS NPC and
astroglial cell proliferation and RAS activity, which is consistent with numerous reports
demonstrating that neurofibromin controls cell proliferation largely by regulating RAS activity in
mouse, swine, and Drosophila cells and tissues. Moreover, the regulation of RAS-mediated cell
proliferation by neurofibromin is further supported using paired hiPSC-derived NPCs,
heterozygous and homozygous for the same NF1 gene mutation, where a clear gene dose
dependency was revealed (C. Anastasaki, manuscript in preparation). As such, the vast majority
of human clinical trials for NF1-null tumors have appropriately employed molecularly targeted
therapies that inhibit RAS and RAS downstream effectors (e.g., MEK) (Dombi et al., 2016).

Second, we demonstrated differential effects of NF1 germline mutations on neuronal
differentiation. These differential effects could reflect the fact that neurofibromin functions as a
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high-affinity dimer, where different mutations could change the overall architecture of the dimer
interface (Sherekar et al., 2020). Since neurons from individuals with NF1 harbor only a single
NF1 germline mutation, different NF1 mutations likely cause unique neuron-related pathologies.
As such, the use of isogenic hiPSCs revealed differential effects of distinct NF1 gene mutations
on NPC proliferation, apoptosis, and neuronal differentiation not previously reported in the
developing Nf1-knockout (Nf1wt/neo) mouse brain. Given the high degree of mutational specificity
for autism symptomatology in children with NF1 (Morris and Gutmann, 2018), these findings
suggest that investigations employing Nf1 mice with different patient germline Nf1 mutations
might uncover unique behavioral abnormalities not appreciated using conventional Nf1 knockout
mice (Costa et al., 2002; Omrani et al., 2015) and identify causative underlying molecular
mechanisms.

Third, the fact that the observed differences in neuronal differentiation in cerebral organoids and
NPC DA levels do not correlate with RAS activation supports the existence of non-RASmediated neurofibromin functions. In this regard, neurofibromin also directly binds to several
proteins important for neuronal differentiation, spinogenesis and serotonin receptor activity,
including collapsin response mediator protein-2 (Patrakitkomjorn et al., 2008), syndecan (Hsueh
et al., 2001), and the 5-hydroxyltryptamine-6 receptor (Deraredj Nadim et al., 2016), through
domains distinct from the GRD. Moreover, the notion that non-RAS-mediated neurofibromin
functions exist in neurons is reinforced by the presence of a neurofibromin isoform containing an
additional amino terminal exon (11alt12), whose expression is restricted to postnatal brain
neurons (Gutmann et al., 1999b). Future investigations aimed at discovering novel neuron-
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specific neurofibromin binding partners will be critical to understanding how NF1 mutations
differentially affect cognition and behavior in children with NF1.

Finally, although population and murine studies provided the first evidence for NF1 genotypephenotype correlations, there had been no direct demonstration of the primary effect of the NF1
mutation at the cellular and tissue levels in humans. The use of this experimental human iPSC
platform revealed NF1 mutational abnormalities in human NPCs and neurons. Collectively, these
studies establish a foundational basis for future studies aimed at unraveling mechanistic
etiologies responsible for NF1-specific CNS phenotypes, discovering new therapeutic targets,
and assessing treatments relevant to precision medicine.
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Chapter 3: hiPSC-derived hCOs harboring a
17q11.2 microdeletion reveal CRLF3 as a
critical regulator of neurogenesis
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3.1 Preface

This chapter is adapted from the following manuscript:
Wegscheid, M.L., et al. Patient-derived iPSC-cerebral organoid modeling of the 17q11.2
microdeletion syndrome establishes CRLF3 as a critical regulator of neurogenesis. Cell Reports
36, 109315 (2021).

Author contributions for the citation above:
M.L.W. and D.H.G designed the experiments. M.L.W., K.A.H., O.M.C., C.A., S.M.M., and
J.B.P. conducted the experiments and/or analyzed the data. S.M.M. and J.N.T. collected patient
specimens. The manuscript was assembled by M.L.W. and D.H.G.
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3.2 Abstract
Neurodevelopmental disorders are often caused by chromosomal microdeletions comprising
numerous contiguous genes. A subset of Neurofibromatosis type 1 (NF1) patients with severe
developmental delays and intellectual disability harbor such a microdeletion event on
chromosome 17q11.2, involving the NF1 gene and flanking regions (NF1 total gene deletion;
NF1-TGD). Using patient-derived human induced pluripotent stem cell (hiPSC)-forebrain
cerebral organoids (hCOs), we identified both neural stem cell (NSC) proliferation and neuronal
maturation abnormalities in NF1-TGD hCOs. While increased NSC proliferation resulted from
decreased NF1/RAS regulation, the neuronal differentiation, survival, and maturation defects
were caused by reduced cytokine receptor-like factor 3 (CRLF3) expression and impaired RhoA
signaling. Furthermore, we demonstrated a higher autistic trait burden in NF1 patients harboring
a deleterious germline mutation in the CRLF3 gene (c.1166T>C, p.Leu389Pro). Collectively,
these findings identify a new causative gene within the NF1-TGD locus responsible for hCO
neuronal abnormalities and autism in children with NF1.

3.3 Introduction
Neurodevelopmental disorders (NDDs) comprise a diverse collection of syndromes in which
affected children exhibit autism spectrum symptomatology, cognitive delays, and intellectual
disabilities. Genomic sequencing and chromosomal analyses have revealed that many NDDs are
associated with chromosomal copy number variations (CNVs) (Coe et al., 2019; Grayton et al.,
2012), leading to altered expression of specific genes. As such, microdeletion syndromes have
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been highly instructive for identifying pathology-causing genes, as well as dissecting the
underlying mechanisms responsible for these neurodevelopmental abnormalities (Frega et al.,
2019; Pucilowska et al., 2018; Ramocki et al., 2010; Shcheglovitov et al., 2013).

Microdeletions on chromosome 17q11.2 most commonly encompass 1.4 Mb of genomic DNA,
including the entire NF1 gene and its flanking regions (type-1 NF1-total gene deletion; NF1TGD). These microdeletion events are found in 4.7-11% of patients with Neurofibromatosis type
1 (NF1; OMIM #162200) (Kluwe et al., 2004; Rasmussen et al., 1998), where children with
NF1-TGD mutations manifest profound developmental delays, intellectual disability (IQ < 70),
and an elevated risk of cancer (Descheemaeker et al., 2004; Mautner et al., 2010; Ottenhoff et al.,
2020; Pasmant et al., 2010; Venturin et al., 2004). While it is possible that these clinical
abnormalities result from the total deletion of one copy of the NF1 gene, the NF1-TGD locus
contains 13 other protein-coding and four microRNA genes, which could also contribute to these
manifestations. To this end, only the deletion of one of these genes, SUZ12, has been previously
correlated with the increased cancer incidence in these patients (De Raedt et al., 2014; Lee et al.,
2014; Wassef et al., 2019; Zhang et al., 2014). In contrast, the underlying molecular etiologies
for the neurodevelopmental deficits in this population are unknown.

To define the molecular and cellular cause(s) for the neurodevelopmental abnormalities in
patients with 17q11.2 microdeletions, we established human induced pluripotent stem cell
(hiPSC)-forebrain cerebral organoid (hCO) models from several NF1 patients with a 1.4 Mb
NF1-TGD mutation (TGD hCOs). Leveraging this platform, we identified neuronal survival,
differentiation, and maturation abnormalities in the TGD hCOs, which were not observed in
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hCOs harboring intragenic NF1 mutations or an atypical deletion (aTGD). Using several
converging strategies, we identified a single gene (CRLF3) and signaling pathway (RhoA
activation) responsible for the neuronal maturation defects observed in TGD hCOs. Moreover,
we demonstrated a higher autistic trait burden in NF1 patients harboring a deleterious germline
mutation in the CRLF3 gene (p.Leu389Pro). Collectively, these experiments reveal a new
causative gene and mechanism responsible for the profound neurodevelopmental abnormalities
of TGD hCOs.

3.4 Materials and methods
Human induced pluripotent stem cells
Patient-derived hiPSC lines were reprogrammed by the Washington University Genome
Engineering and iPSC Core Facility (GEiC) using biospecimens (skin, blood, urine) acquired
from three individuals harboring a 1.4 Mb NF1-total gene deletion (TGD) and one patient
harboring an atypical TGD (aTGD) (Table 3.1) with an established diagnosis of NF1 under an
approved Human Studies Protocol at Washington University. As atypical TGD mutations are
rare in the NF1 population (Messiaen et al., 2011), no additional patients with this genomic
alteration were available to generate hiPSC lines. Briefly, fibroblasts, renal cells or peripheral
blood cells were infected with a Sendai virus carrying four stem cell reprogramming factors
(OCT4, KLF4, SOX2, C-MYC), as previously reported (Anastasaki et al., 2020; Anastasaki et al.,
2015). hiPSC colonies were isolated and pluripotency was confirmed by morphological
assessment and expression of stem cell markers (Figure 3.1A). Two to three different clones
were expanded for each line, tested, and verified negative for Mycoplasma contamination, and
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used to generate human cerebral organoids (hCOs) (Figure 3.1B-E), neural stem cells (NSCs)
(Figure 3.7H) and neurons. The sizes of the NF1 locus deletions were determined by MLPA
assay (MRC Holland) at the Medical Genomics Laboratory (University of Alabama,
Birmingham). Single clones of two patient-derived neurologically normal controls were provided
by Drs. Matthew B. Harms (CTL2, male) and Fumihiko Urano (CTL3, male) at Washington
University. Five distinct isogenic human induced pluripotent stem cell (hiPSC) lines harboring
NF1 patient germline NF1 gene mutations (Transcript ID NM_000267; c.1149C>A,
c.1185+1G>A, c.3431-32_dupGT, c.5425C>T, c.6619C>T) were individually engineered into a
single commercially available male control human iPSC line (BJFF.6, CTL1) as previously
described (Anastasaki et al., 2020) (Table 3.1). All hiPSC lines generated by CRISPR/Cas9
engineering were subjected to subcloning and Illumina deep sequencing to verify the presence of
the introduced mutation. These renewable resources are continuously frozen at low passage (<
5). All hiPSC clones were used for analysis and relative to prior frozen aliquots of the same
clone to ensure reproducibility. hiPSCs have been authenticated by (a) routine testing
for Mycoplasma infection, (b) regular quality control checks for pluripotency by monitoring
expression of pluripotency markers, and (c) competence to undergo multi-lineage
differentiation.

Human subject details
Samples for exome sequencing were acquired from a previously assembled cohort of individuals
with NF1 from Washington University Neurofibromatosis Center whose DNA was banked under
a Human Studies protocol approved by the Washington University Human Research Protection
Office (Constantino et al., 2015). Informed consent was obtained from all participants. Patients
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with copy number variants (CNVs) (n = 1) were excluded. Of the patients between 10 and 19
years of age with clinically indicated SRS-2 testing, 11 were male (64.7%) and 6 were female
(35.3%). Selected individuals ranged in age from 10 to 18 years (median, 13 years), with SRS-2
T scores from 45 to 98 (Table 3.2). There was no significant difference between males (n = 11)
and females (n = 6) with respect to SRS-2 scores, between males (n = 5) and females (n = 2) in
the group with a deleterious p.Leu389Pro CRLF3 mutation (n = 7), or between males (n = 6) and
females (n = 4) without a CRLF3 mutation (n = 10).

Human iPSC, cerebral organoid, NSC and 2D neuron cultures
hiPSCs were cultured on Matrigel (Corning)-coated culture flasks and were fed daily with
mTeSR Plus (05825, STEMCELL Technologies). hiPSCs were passaged with ReLeSR (05873,
STEMCELL technologies) following manufacturer’s instructions. hCOs were generated as
previously described (Anastasaki et al., 2020). Briefly, cerebral organoids were cultured from
hiPSCs by first aggregating 40,000 hiPSCs per well of an ultra-low binding 96-well U-bottom
plate (Corning) to allow for embryoid body (EB) formation. EBs were fed every other day with
STEMdiff Neural Induction Medium (05835, STEMCELL technologies) supplemented with low
concentration bFGF (4ng/mL; 100-18B, PeproTech) and ROCK inhibitor (20 µM; Y27632,
Millipore) for the first 6 days, followed by NIM minus bFGF and ROCK inhibitor for an
additional 3 days. Tissues were then transferred to Corning Costar 24 Well Clear Flat Bottom
Ultra Low Attachment plates (1 organoid per well) in hCO differentiation medium (125 ml
DMEM-F12, 125 ml Neurobasal medium, 1.25 ml N2 supplement, 62.5 µl insulin, 2.5 ml
GlutaMAX supplement, 1.25 ml MEM-NEAA, 2.5 ml B27 supplement, 2.5 ml penicillinstreptomycin, 87.5µl of a 1:100 dilution of 2-mercaptoethanol in DMEM-F12) on an orbital
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shaker rotating at 80 rpm. hCO differentiation media was changed every 3 days. hCOs were
maintained for up to 84DIV. Neural progenitor cells (NSCs) were generated using previously
described methods (Anastasaki et al., 2020). For non-specific neuronal differentiation, NSCs
were cultured in PLO/Laminin-coated plates in neuronal differentiation media (490 ml
Neurobasal media, 5 ml N2 supplement, 5 ml MEM-NEAA ) supplemented with 0.01 µg/ml
BDNF (450-02, PeproTech), IGF-I (100-11, PeproTech), GDNF (78058, STEMCELL
technologies), cAMP (1µM; 1698950, PeproTech), and Compound E (0.2 µM; 73954,
STEMCELL technologies) for 7 days.

Whole exome sequencing
Genomic DNA samples were whole exome sequenced (Otogenetics Ltd), and FASTQ files
aligned to the human reference genome assembly (GRCh37/hg19) using Samtools 1.4.1
software. Sequence variants of CRLF3 were called, filtered, and prioritized according to their
impact annotation obtained from SnpEff. Pathogenicity of resulting variants was additionally
confirmed using CADD, SIFT, PolyPhen, likelihood ratio test (LRT), GERP++, and Fathmm.

Next generation RNA sequencing and analysis
RNA sequencing (RNA-seq) was performed on CTL1, CTL2, TGD1, TGD2, TGD3, aTGD and
shCRLF3-1 NSCs as previously described (Anastasaki et al., 2020). Sequencing analyses were
generated using Partek Flow software, version 9.0.20 (Partek Inc, 2020). RNA-seq reads were
aligned to the Ensembl transcripts release 100 top-level assembly with STAR version 2.7.3a
(Dobin et al., 2013). Gene counts and isoform expression were derived from Ensembl output.
Sequencing performance was assessed for the total number of aligned reads, total number of
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uniquely aligned reads, and features detected. Normalization size factors were calculated for all
gene counts by median ratio. Differential genetic analysis was then performed using DESeq2
(Love et al., 2014) to analyze for differences between conditions. Results for TGD samples
compared separately with CTLs and aTGD samples were filtered for only those genes with P
values and false discovery rates (FDR)  0.01 and log fold-changes ≥  5. This gene list was then
filtered further for only non-significant genes in the comparison of TGD samples vs shCRLF3
samples. This resulted in a gene list of 31 genes (Table 3.3). Gene Ontology enrichment
(Ashburner et al., 2000) was run on the resulting gene list. Deep sequencing data is in the process
of being submitted to GEO.

Immunohistochemistry
hCOs were fixed, embedded and cryosectioned at 12 µm as previously described (Sloan et al.,
2018). Tissues were permeabilized in 0.5% Triton X-100 in PBS for 5 minutes. After three PBS
washes, tissues were blocked in a solution of 10% goat serum (GS) in PBS for one hour at room
temperature, then immunolabeled with primary antibodies, diluted in a solution of 2% GS,
overnight at 4ºC. The following primary antibodies were used: anti-SOX2 (1:400, 4900, Cell
Signaling Technology), anti-SOX2 (1:200, ab92494, Abcam), anti-OCT4A (1:400, 2840, Cell
Signaling Technology), anti-NANOG (1:800, 3580, Cell Signaling Technology), anti-SMI-32
(2.5 µg/mL, 801701, Biolegend), anti-SMI-312 (2.5 µg/mL, 837904, Biolegend), anti-NeuroD1
(1:250, ab205300, Abcam), anti-NeuroD1 (1:500, ab60704, Abcam), anti-NeuN (1:500,
MAB377, Millipore), anti-Ki67 (1:100, BD556003, BD Biosciences), anti-MAP2 (1:500,
ab11267, Abcam), anti-cleaved caspase-3 (1:250, 9664, Cell Signaling Technology), anti-active
caspase-3 (1:100, AF835, R&D systems), anti-PAX6 (1:250, ab19504, Abcam), anti-OTX2
57

(1:200, MA5-15854, Thermo Fisher Scientific), anti-EN1 (1:50, PA5-14149, Thermo Fisher
Scientific), anti-GBX2 (1:50, LS-C197281, Lifespan Biosciences), anti-TBR1 (1:200, ab31940,
Abcam), anti-SATB2 (1:100, ab51502, Abcam), anti-Vimentin (1:100, 5741, Cell Signaling
Technology), anti-Nestin (1:250, ab92391, Abcam). The following day, slides were washed three
times with PBS and labelled with relevant secondary antibodies [AlexaFluor488/568 (1:200,
Invitrogen)] for one hour at room temperature. Hoechst (1:5000 in PBS) was used for cell
nucleus staining. For EdU pulse-chase analyses, 16DIV hCOs were incubated with 10 µM EdU
for 1.5 hours. EdU staining was performed using Click-IT EdU Alexa Fluor 488 Imaging Kit
(C10337, Invitrogen). TUNEL assays were performed using In Situ Cell Death Detection Kit,
Fluorescein (11684795910, Roche). All imaging was done on a Leica fluorescent microscope
(Leica DMi8) using Leica Application Suite X software for initial processing. Cell counter
plugin of ImageJ was used to quantify cells in images of immunolabeled hCOs.

RAS, Rac1, and RhoA activity assays
For small molecule treatments, 14DIV hCOs were incubated with 10 µM Pan-RAS-IN-1 (HY101295, MedChemExpress) for 48 hours, and RAS activity (STA-440, Cell Biolabs) was
determined on liquid nitrogen snap frozen specimens according to the manufacturer’s
instructions. NSCs or 8DIV EBs were treated for 24h with 1 µg/ml Rho Activator II (CN-03;
Cytoskeleton; CN03) to induce Rho activation. RhoA (BK124, Cytoskeleton) and Rac1 (BK128,
Cytoskeleton) activity assays were performed on liquid nitrogen snap frozen NSC and hCO
specimens, according to the manufacturer’s instructions.
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Real-time quantitative PCR
Total RNA was extracted (RNeasy Mini Kit, Qiagen) from hiPSC-derived hCOs according to
manufacturer’s instructions. RNA concentrations and purity were assessed using a NanoDrop
2000 Spectrophotometer prior to reverse transcription using a high-capacity cDNA reverse
transcription kit (4374966, Applied Biosystems). RT-qPCR was performed using TaqMan gene
expression assays [CRLF3 (Hs00367579_m1), ATAD5 (Hs00227495_m1), TEFM
(Hs00895248_m1), ADAP2 (Hs01106939_m1), COPRS (Hs01047650_m1), UTP6
(Hs00251161_m1), SUZ12 (Hs00248742_m1), LRRC37B (Hs03045845_m1), MIR193A
(Hs04273253_s1), MIR365B (Hs04231549_s1), MIR4725 (Hs06637953_s1), MIR4733
(Hs04274676_s1)] and TaqMan Fast Advanced Master Mix, no UNG (4444964, Applied
Biosystems) according to manufacturer’s instructions. All reactions were performed using the
Bio-Rad CFX96 Real-Time PCR system equipped with Bio-Rad CFX Manager 3.1 software.
Gene expression levels of technical replicates were estimated by ΔΔCt method using GAPDH
(Hs02786624_g1) as a reference gene.

Western blot analysis
hCO, NSC and iPSC samples were collected, sonicated in RIPA buffer (89900, Thermo
Scientific) containing 2 µg/mL aprotinin (ab146286, Abcam), 10 µg/mL leupeptin (L2884,
Sigma-Aldrich), and 1 mM PMSF (10837091001, Sigma-Aldrich), and total protein
concentrations determined (Pierce BCA protein assay kit, 23225, Thermo Scientific). Reducing
Laemmli buffer (1610747, Bio-Rad) was added and samples incubate at 95ºC for 5 minutes.
Equal amounts of protein (30 to 45 µg) were loaded into each well of 8% or 10% SDS-PAGE
gels and run for 1.5 hours at 120 V, followed by transfer to polyvinylidene fluoride membranes
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using an Invitrogen power blotting system. The membranes were blocked for 1 hour in 5 % milk
in Tris-buffered saline (TBS), followed by incubation overnight at 4ºC with primary antibodies
in TBS: anti-SUZ12 (1 µg/mL, ab12073, Abcam), anti-COPRS (1:500, NBP2-30884, Novus
Biologicals), anti-CRLF3 (1:100, HPA007596, Sigma-Aldrich), anti-ATAD5 (1:500, LSC19118, Lifespan Biosciences), anti-UTP6 (1:300, 17671-1-AP, Proteintech), anti-N-cadherin
(1:1000, ab18203, Abcam), anti-neurofibromin (1:100, manuscript in preparation), anti-Vinculin
(1:5000, ab129002, Abcam) and anti-GAPDH (1:2,000, ab8245, Abcam). After washing with
TBS, blots were incubated with a 1:5,000 dilution of goat anti-rabbit IRDye 680RD (926-68071,
LI-COR Biosciences) and goat anti-mouse IRDye 800CW (925-32210, LI-COR Biosciences)
secondary antibodies in TBS for one hour at room temperature. Imaging of immunoblots was
performed using a LI-COR Odyssey Fc imaging system (LI-COR Biosciences). Protein bands
were quantified using LI-COR Image Studio Software v5.2, and experimental protein values
were normalized to GAPDH or Vinculin as an internal loading control.

RNA interference
CTL1 hiPSCs were infected with four independent CRLF3 shRNA lentiviral particles (sc-94066V, Santa Cruz Biotechnology; shCRLF3 A: AAAGGCTTCGCACATTCAGTTGGACAGCT;
shCRLF3 B: TACAGTCTGAGCAGTCGAAGAAATATAGC; shCRLF3 C:
GACATTGAAGCCGTGACTCTAGGAACCAC; TL305215V, Origene) (MOI = 5) or control
shRNA lentiviral particles (sc-108080, Santa Cruz Biotechnology; TR30021V shRNA scramble
control particles, Origene) (MOI = 5). Infected cultures were incubated with mTeSR Plus
medium (05825, STEMCELL Technologies) containing 0.4 µg/mL puromycin (73342,
STEMCELL Technologies) for selection, and the medium was replaced every other day until
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drug-resistant colonies formed (~14 days). Resulting colonies were expanded, assayed for
CRLF3 gene expression by Western blotting and were differentiated into NSCs or hCOs.

Ortholog sequence comparison
NCBI’s Eukaryotic Genome Annotation pipeline was used to identify vertebrate orthologs of
human CRLF3. Amino acid sequence alignments were generated by NCBI’s constraint-based
multiple alignment tool (Cobalt) that finds a collection of pairwise constraints derived from
conserved domain database, protein motif database, and sequence similarity, using RPS-BLAST,
BLASTP, and PHI-BLAST (Papadopoulos and Agarwala, 2007). Alignment results were
visualized by Jalview.

Quantification and statistical analysis
No statistical methods were used to predetermine sample size. Sample size was deemed
satisfactory based on the magnitude and consistency of differences between groups. No
randomization of samples was performed, and investigators were not blinded during experiments
and outcome assessment. Image fields for NeuroD1+ neuronal quantifications were selected from
the inner subventricular zones of hCOs. Image fields for NeuN+, TBR1+ and SATB2+ neuronal
quantifications were selected from the outer subventricular zones of hCOs. The number of
biological replicates (hCOs) per independent experimental replicate per genotype is provided in
the figure legends. For each genotype, all available clones were analyzed. All statistical analyses
were performed using GraphPad Prism 8 software. Statistical significance was determined using
one-way analysis of variance (ANOVA) with Dunnett’s multiple comparisons test, Bonferroni
multiple comparisons test, Tukey multiple comparison’s test, two-way ANOVA with Sidak’s
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multiple comparison test, or unpaired, two-tailed t-test. The exact values from the tests are
indicated in the figures. Statistical significance was defined as P < 0.05. Bar graphs indicate the
mean ± SEM. Box plot indicates median (central line), interquartile range (box) and minimum
and maximum values (whiskers).

A summary table summarizing all the experiments is included in Table 3.4, discriminating the
samples in each figure panel with the statistical methods used for analysis.

3.5 Results
TGD hCOs have neuronal defects
Using hCOs from three neurologically normal control individuals and three individuals
harboring a 1.4 Mb NF1-TGD (Figure 3.2A, Table 3.1, Figure 3.1A-E), we first assessed
neural stem cell (NSC) proliferation. Similar to hCOs harboring intragenic NF1 patient NF1 gene
point mutations (Anastasaki et al., 2020) (Table 3.1), TGD hCOs also exhibited increased NSC
proliferation (%Ki67+ NSCs per hCO ventricular zone [VZ]) at 16 and 35 days in vitro (DIV)
(Figure 3.2B, D) and 5-ethynyl-2′-deoxyuridine (EdU) incorporation at 16DIV (Figure 3.3A)
relative to control hCOs.

Next, to assess the temporal course of neurogenesis in these PAX6+/OTX2+ dorsal telencephalic
forebrain hCOs (Figure 3.1E), cryosections were immunostained for markers of early(NeuroD1+) and late- (NeuN+) stage immature neurons, as well as deep- (TBR1+) and upperlayer (SATB2+) neurons (Figure 3.2C, 3.1F-G). The TGD hCOs produced increased numbers of
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NeuroD1+ immature neurons relative to control hCOs from 16 to 56DIV (Figure 3.2E), after
which time, NeuroD1+ neurons were no longer present. Late-stage immature NeuN+ neurons and
deep-layer TBR1+ neurons were first detected at 35DIV in both control and TGD hCOs;
however, the TGD hCOs had reduced numbers of NeuN+ and TBR1+ neurons (Figure 3.2F,
3.1G) at 35 and 56DIV. Despite normalization of NeuN+ neuronal numbers at 84DIV (Figure
3.2F) and no microcephalic defects (Figure 3.1B-D), the TGD hCOs had reduced numbers of
upper-layer SABT2+ neurons at 84DIV (Figure 3.1H), demonstrating a persistent imbalance in
the neuronal subtypes generated. This impaired neuronal differentiation was unique to the TGD
hCOs, as it was not observed in hCOs harboring five distinct intragenic NF1 gene mutations
(Table 3.1, Figure 3.3B).

As the increased numbers of early-stage immature neurons in the TGD hCOs did not generate a
compensatory increase in late-stage immature neurons, we hypothesized that the TGD NeuroD1+
neurons were being eliminated by programmed cell death. To measure apoptosis, 35 and 56DIV
hCOs were immunolabeled for the early- (cleaved caspase-3) and late-stage (TUNEL) apoptotic
markers, respectively. Greater caspase-3 cleavage (11.8% increase; Figure 3.2G-H) and DNA
fragmentation (6.3% TUNEL increase; Figure 3.3C) were observed in the TGD NeuroD1+
neurons relative to controls, establishing a concurrent increase in production and apoptosis of
early-stage immature neurons in TGD hCOs. The increased apoptosis of NeuroD1+ neurons in
TGD hCOs, coupled with differentiation of the remaining NeuroD1+ neurons in TGD hCOs at
56DIV, accounts for normalization of late-stage immature neurons at 84DIV.
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The finding of neuronal differentiation defects in the TGD hCOs prompted us to determine
whether there were also defects in dendrite and axonal extension, as reported in children with
autism spectrum disorder (ASD) and intellectual disability (Hutsler and Zhang, 2010; Lazar et
al., 2014; Mukaetova-Ladinska et al., 2004; Wolff et al., 2012). While the TGD hCOs produced
normal SMI-312+ axonal projections, they had reduced MAP2+ and SMI-32+ dendrites in hCOs
from 35 to 84DIV (Figure 3.2I; 3.1F; 3.3D-E), abnormalities not observed in hCOs harboring
intragenic NF1 mutations (Figure 3.3F). Similar to TGD hCOs, hiPSC-derived neurons in 2D
cultures also exhibited reduced MAP2+ and SMI-32+ dendrites (Figure 3.2J). Taken together,
these results reveal that TGD hCOs and hCOs harboring intragenic NF1 mutations have
increased NSC proliferation, reflecting impaired NF1 gene function, but additionally exhibit
neuronal abnormalities (dendritic maturation) unique to TGD hCOs.

NSC hyperproliferation in TGD hCOs is RAS-dependent
To further explore the impact of complete NF1 deletion on NSC proliferation in the absence of
other genetic contributors, we generated hCOs from the single available patient-derived hiPSC
line harboring a rare atypical (0.6-0.9 Mb) deletion (aTGD), involving the loss of six proteincoding genes, including NF1, but not the eight protein-coding genes deleted in the common 1.4
Mb NF1-TGD (Figure 3.4A). Similar to the TGD and intragenic NF1-mutant hCOs (Anastasaki
et al., 2020), the aTGD hCOs had increased NSC proliferation (%Ki67+ NSCs; Figure 3.4B)
relative to controls. Since the NF1 protein (neurofibromin) has previously been shown to mediate
increased cell proliferation through RAS regulation in numerous NF1-mutant cell types (Chen et
al., 2015; Hegedus et al., 2007; Lee et al., 2010; Sanchez-Ortiz et al., 2014; Wang et al., 2012),
we hypothesized that the increased NSC proliferation observed in the NF1-mutant hCOs was
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RAS-dependent. Similar to the intragenic NF1-mutant hCOs (Anastasaki et al., 2020), TGD and
aTGD hCOs had increased RAS activity (1.4 and 2.1-fold, respectively) relative to controls
(Figure 3.4C). To investigate the relationship between RAS hyperactivation and increased NSC
proliferation in the NF1-mutant hCOs, we incubated control, TGD, and aTGD hCOs with an
experimentally determined concentration of the pan-RAS inhibitor IN-1 (IN-1) for 48 hours
(Figure 3.5A-C). While IN-1 had no effect on NSC proliferation in control hCOs (Figure 3.5D)
or neuronal differentiation and dendrite maturation in TGD and aTGD hCOs (Figure 3.5E-F), it
reduced the NSC hyperproliferation in TGD and aTGD hCOs (Figure 3.4D), confirming that
RAS hyperactivation is solely responsible for the increased NSC proliferation observed in NF1mutant hCOs.

TGD hCOs have reduced CRLF3 expression
In striking contrast to the TGD hCOs, the aTGD hCOs lacked neuronal survival, differentiation
and maturation abnormalities. In this regard, the aTGD hCOs produced normal numbers of latestage immature neurons (Figure 3.4E), exhibited no increase in immature neuron apoptosis
(Figure 3.4F), and had normal dendrites (Figure 3.4G) relative to controls. These observations
demonstrate that genes outside of the atypical deletion region are responsible for the neuronal
differentiation and maturation defects observed in the TGD hCOs.

To identify the responsible gene(s), we conducted a systematic analysis of the genes contained
within the 1.4 Mb deletion region, but not in the atypical deletion region (Figure 3.6A). First, the
deletion status of two genes in the aTGD hCOs (COPRS and RAB11FIP4) was assayed by RTqPCR (Figure 3.6B, 3.5G), revealing reduced expression of RAB11FIP4 (within the aTGD
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region), but not COPRS (outside the aTGD region). Next, we excluded the three microRNA
genes that exhibited highly variable mRNA expression (Figure 3.5H), as well as one proteincoding gene (ADAP2) and one microRNA gene (MIR4733), which were not expressed in control
hCOs. We then analyzed the differential gene expression of the seven remaining protein-coding
genes at an experimentally-determined time point where the highest levels of mRNA expression
were detected in control hCOs (Figure 3.5I).

All seven genes had reduced mRNA expression in the TGD hCOs relative to controls (Figure
3.6B). However, cytokine receptor-like factor 3 (CRLF3) was the only gene with reduced protein
levels in the TGD hCOs relative to the aTGD and control hCOs (82% and 66%, respectively)
(Figure 3.6B-C, 3.5J-N), implicating CRLF3 in the neuronal defects observed only in TGD
hCOs.

CRLF3 mutation is associated with increased autism trait burden in patients with NF1
To further investigate CRLF3 as a potential gene involved in neurodevelopment, we evaluated
CRLF3 mutation status in a previously assembled cohort of individuals with NF1 from the
Washington University NF Center. We specifically chose patients who underwent Social
Responsiveness Scale, second edition (SRS-2) testing as part of routine NF1 clinical screening,
had DNA banked under an approved Human Studies protocol (Constantino et al., 2015), and
were between the ages of 10 and 19, based on the World Health Organization’s definition of
adolescence (World Health, 2017) and previously described age-dependent differences in autistic
trait burden in children, adolescents, and adults with NF1 (Morris et al., 2016b). After excluding
patients with CNVs (n = 1), 17 patients were analyzed (Table 3.2).
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Genomic DNA was whole-exome sequenced (WES) to identify genetic variants, which were
prioritized according to their annotated impact (STAR Methods). A single deleterious CRLF3
missense mutation (c.1166T>C, p.Leu389Pro) affecting a highly conserved amino acid within
the CRLF3 protein (Figure 3.7A) was identified in 7/17 of the NF1 patients (Figure 3.6D).
Grouping of patients by CRLF3 c.1166T>C mutation status revealed higher SRS-2 scores in NF1
patients with the mutation than in those without it (P = 0.0374) (Figure 3.6E). The neuronal
differentiation, survival, and maturation abnormalities in TGD hCOs harboring a heterozygous
CRLF3 deletion, coupled with the observed increase in autistic trait burden in patients harboring
a deleterious mutation in the CRLF3 gene, suggests an essential role for CRLF3 in human brain
development. This notion is further supported by the high amino acid sequence conservation of
CRLF3 across vertebrates (Hahn et al., 2019; Hahn et al., 2017; Ostrowski and Heinrich, 2018)
and enriched CRLF3 expression found in human embryonic brain tissues (Yang et al., 2009)
(Figure 3.7B).

CRLF3 reduction recapitulates the TGD neuronal defects
To determine whether reduced CRLF3 expression was responsible for the neuronal maturation
defects observed in TGD hCOs, control hiPSCs were infected with four unique CRLF3
(shCRLF3) and four unique control (shCTL) short hairpin RNA constructs. All four shCRLF3
constructs had reduced CRLF3 expression relative to shCTLs (Figure 3.8A, 3.7C). While
CRLF3 reduction had no effect on NSC proliferation (Figure 3.8B) or neurofibromin protein
expression and subcellular localization (Figure 3.7D-F), it fully replicated the neuronal
abnormalities observed in the TGD hCOs. In this regard, shCRLF3 hCOs had increased numbers
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of early-stage immature neurons at 16DIV, reduced numbers of late-stage immature neurons at
35DIV (Figure 3.8C), increased immature neuron apoptosis (Figure 3.8D), reduced SMI-32+
dendrites (Figure 3.8E) and SATB2+ upper layer neurons (Figure 3.7G) compared to shCTL
hCOs. These results demonstrate that reduced CRLF3 expression is sufficient to produce the
TGD neurogenic abnormalities, establishing CRLF3 as a key regulator of human neuron
differentiation, survival, and maturation.

CRLF3-mediated dendritic defects result from impaired RhoA activation
To gain mechanistic insights into CRLF3-mediated signaling in human brain cells, we performed
RNA sequencing on CTL, TGD, shCRLF3 and aTGD NSCs (Figure 3.8F-G, 3.7H). First, we
identified differentially-expressed genes (DEGs; P values, false discover rates (FDR) ≤ 0.01;
log-fold changes ≥ ±5) in TGD NSCs relative to CTL and aTGD NSCs. This DEG list was
filtered for non-significant genes in the comparison of TGD and shCRLF3 NSCs (Table 3.3).
Subsequent gene ontology (GO) enrichment analysis demonstrated δ-catenin binding as the most
highly enriched GO term (Figure 3.8G). Notably, dysregulation of δ-catenin signaling has been
implicated in autism (Turner et al., 2015), dendritic spine morphogenesis, maintenance and
function during development (Arikkath et al., 2009; Matter et al., 2009) through regulation of Ncadherin levels (Fukata and Kaibuchi, 2001; Tan et al., 2010) and activation of Rho-family
GTPases, RhoA and Rac1 (Arikkath et al., 2009; Elia et al., 2006; Gilbert and Man, 2016). To
determine whether CRLF3 regulates this pathway in cells and tissues harboring a TGD, we
measured N-cadherin protein levels, as well as Rac1 and RhoA activation in CTL, TGD and
shCRLF3 NSCs (Figure 3.8H-K, 3.7I-K). Consistent with this mechanism, TGD and shCRLF3
NSCs had reduced N-cadherin levels (TGD, 65% reduction; shCRLF3, 52% reduction; Figure
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3.8H, 3.7I), decreased Rac1 activation (TGD, 18.5% reduction; Figure 3.8I; shCRLF3, 13.1%
reduction; Figure 3.7J), and decreased RhoA activation (TGD, 76.6% reduction; Figure 3.8J;
shCRLF3, 77.1% reduction; Figure 3.8K) relative to controls. Moreover, treatment of TGD and
shCRLF3 hCOs with an experimentally determined concentration of RhoA activator CN03
(Figure 3.7K) rescued the neuron maturation (TGD, 35.8% reduction in NeuroD1, 1.9-fold
increase in NeuN; shCRLF3, 57.7% reduction in NeuroD1, 2.6-fold increase in NeuN; Figure
3.8L-M; 3.7L), neuron apoptosis (TGD, 23% reduction; shCRLF3, 17.6% reduction in Cl.
Caspase-3; Figure 3.8N; 3.7M) and dendrite maturation defects (TGD, 2.5-fold increase;
shCRLF3, 2.6-fold increase in SMI-32 immunopositivity; Figure 3.8O; 3.7N) to control levels
in 35DIV hCOs. These results establish reduced RhoA signaling as the etiologic mechanism
responsible for the impaired neuron maturation and neurite outgrowth in TGD hCOs.

69

3.6 Figures and tables
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Figure 3.1 | Patient-derived hiPSCs and hCOs.
(A) Representative images of hiPSCs immunolabeled for pluripotency markers OCT4A,
NANOG, and SOX2. Scale bars: 50 µm. (B) Representative bright-field images of hCOs at 16,
35 and 56DIV. Scale bars: 1 mm. (C-D) Quantification of surface areas of hCOs at (C) 16DIV
and (D) 84DIV. (E) Representative immunofluorescence images of 16DIV CTL (CTL1), TGD
(TGD1) and aTGD hCOs immunolabeled for dorsal forebrain (PAX6, OTX2), midbrain (OTX2,
EN1) and hindbrain (GBX2) markers. Scale bars: 50 µm. (F) (related to Figure 3.2I)
Quantitation of SMI-32+ immunopositive dendrites in 35DIV TGD relative to CTL hCOs. (G)
Representative images of 35DIV CTL and TGD hCOs immunolabeled for early-stage immature
neurons (NeuroD1) and deep-layer cortical neurons (TBR1) and quantification of the number of
TBR1+ deep-layer neurons per image field in hCOs at 35DIV. (H) Representative images of
84DIV CTL and TGD hCOs immunolabeled for deep-layer (TBR1) and upper-layer (SATB2)
neurons and quantification of %SATB2+ upper-layer neurons in hCOs at 84DIV. Scale bars, 100
µm. Independent hiPSC lines representing three different CTL or TGD lines (black, CTL1 /
TGD1; white, CTL2 / TGD2; red, CTL3 / TGD3) are shown. Data are expressed as the mean ±
SEM. Each data point represents one hCO, 2-6 hCOs per experimental replicate, 3-5
experimental replicates per genotype. Statistical analysis by unpaired, two-tailed t-test or oneway ANOVA with Bonferroni multiple comparisons test.
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Figure 3.2 | TGD hCOs and neurons exhibit neuronal defects.
(A) Protein-coding genes within the 17q11.2 microdeletion region, denoting the length and
location of the 1.4 Mb deletion (adapted (Kehrer-Sawatzki et al., 2017)). (B, D) Images and
quantification of VZ NSC proliferation (Ki67+, red) in control (CTL) and TGD hCOs at 16 and
35DIV. (C) Images of 35DIV hCOs immunolabeled for NeuroD1+ (green) and NeuN+ (red)
neuronal markers. (E-F) Number of (E) NeuroD1+ and (F) NeuN+ neurons per image field in the
SVZs of TGD hCOs relative to CTL. (G) Increased apoptotic immature neurons in TGD hCOs
compared to CTL at 35DIV. (D-G) Each data point represents one hCO, 2-6 hCOs per
experimental replicate, 3-5 experimental replicates per genotype. Independent hiPSC lines
representing three different CTL or TGD lines (black, CTL1/ TGD1; white, CTL2/ TGD2; red,
CTL3/ TGD3) are shown. (H) White arrowheads indicate co-localization of NeuroD1+ neurons
(red) and cleaved caspase-3 (green) in CTL and TGD hCOs at 35DIV. (I) Images of hCOs
immunolabeled for dendrites (MAP2+, SMI-32+) and axons (SMI-312+) at 35DIV. (J) Images of
2D CTL and TGD neurons immunolabeled for SMI-32, with a graph depicting the mean dendrite
lengths per genotype. Three independent experimental replicates per genotype, 48-112 neurites
per replicate. Data are shown as the mean ± SEM. Statistical analyses by unpaired, (D-G) twotailed t-test or (J) one-way ANOVA. Scale bars: B-I: 50µm, J: 100µm.
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Figure 3.3 | Neuronal differentiation defects in TGD and intragenic NF1-mutant hCOs.
(A) %EdU+ neural stem cells (NSCs) in 16DIV CTL and TGD hCOs. (B) Quantification of latestage immature (NeuN+) neurons per image field in the SVZ of intragenic NF1-mutant hCOs
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relative to CTL hCOs at 35DIV. (C) Representative images and quantification of CTL and TGD
hCOs immunolabeled for TUNEL (green) and NeuroD1 (red) (co-localization indicated by white
arrows) at 56DIV. (A-C) Independent hiPSC lines (black, CTL1 / TGD1; white, CTL2 / TGD2;
red, CTL3 / TGD3) are shown. (D-E) Representative images of CTL and TGD hCOs
immunolabeled for MAP2+ and SMI-32+ dendrites at (D) 56DIV and (E) 84DIV. (F)
Representative control (CTL1) and intragenic NF1-mutant hCOs immunolabeled for dendritespecific markers (MAP2+, SMI-32+) at 35DIV. Data are shown as the mean ± SEM. Each data
point represents one biological replicate (hCO), 2-6 biological replicates per experimental
replicate, 3-5 experimental replicates per genotype. Statistical analysis by unpaired, two-tailed ttest or one-way ANOVA with Dunnett’s multiple comparisons test. Scale bars: 50 µm.
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Figure 3.4 | RAS hyperactivation drives the increased NSC proliferation in TGD hCOs.
(A) Diagram illustrating the 1.4 Mb (TGD) and atypical (aTGD) microdeletions, highlighting
their commonly deleted region. (B) Images and quantification of NSC (SOX2+) proliferation
(Ki67+) in CTL and aTGD hCOs at 16 and 35DIV. (C) TGD and aTGD hCOs have increased
RAS activity relative to CTL hCOs at 16DIV. Each data point represents an independent
experimental replicate consisting of 4 pooled hCOs. (D) Images and quantification of NSC
proliferation (fold change in %Ki67+ NSCs) in three clones of TGD and aTGD hCOs at 16DIV
with or without IN-1 treatment. (E-G) Images and quantification of CTL and aTGD hCOs
showing normal (E) production of NeuN+ neurons at 35 and 56DIV, (F) early-stage immature
neuron apoptosis, and (G) production of dendrites (MAP2+, SMI-32+) and axons (SMI-312+) at
35DIV. (B, D-F) Each data point represents one hCO, 2-6 hCOs per experimental replicate, 3-5
76

experimental replicates per genotype. Independent hiPSC lines representing three different CTL
or aTGD lines (black, CTL1/ aTGD1; white, CTL2/ aTGD2; red, CTL3/ aTGD3) are shown. All
data are shown as the mean ± SEM. Statistical analysis by one-way ANOVA with Dunnett’s
multiple comparisons test or unpaired, two-tailed t-test. Scale bars: 50µm.
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Figure 3.5 | RAS activity and differential gene expression analysis of TGD and CTL hCOs.
(A) RAS activation in CTL and TGD 8DIV embryoid bodies and 16DIV hCOs. (B-C) Reduced
RAS activity in (B) TGD3 and aTGD 16DIV hCOs and (C) CTL1 and CTL2 hCOs following 10
µM pan-RAS-IN-1 (IN-1) treatment. The mean CTL hCO RAS activity was assigned a value of
1 (dotted line). (A-C) Each data point represents an independent experimental replicate
consisting of 20 pooled embryoid bodies or 4 pooled hCOs. Statistical analysis by unpaired, twotailed t-test or one-way ANOVA with Dunnett’s multiple comparisons. (D) Quantification of
NSC proliferation (fold change in %Ki67+ NSCs) in control hCOs at 16DIV with or without IN1 treatment. Each data point represents one hCO, 2-6 hCOs per experimental replicate, 3-5
experimental replicates per genotype. Statistical analysis by unpaired, two-tailed t-test. (E)
Number of early-stage immature (NeuroD1+) neurons per image field in the SVZ of 16DIV
TGD3 and aTGD hCOs with and without IN-1 treatment. Each data point represents one hCO, 312 hCOs per clone. Statistical analysis by unpaired, two-tailed t-test comparing TGD3 and aTGD
hCOs with control values (indicated by dotted line). (A-E) All data are shown as the mean ±
SEM. Independent (A, E) hiPSC lines (black, CTL1 / TGD1 / aTGD1; white, CTL2 / TGD2 /
aTGD2; red, CTL3 / TGD3, aTGD-3), or (C-D) independent hiPSC clones (black, clone 1;
white, clone 2; red, clone 3) are shown. (F) Representative images of 16DIV TGD3 and aTGD
hCOs with and without RAS-IN-1 treatment immunolabeled for MAP2+ dendrites. Scale bars: 50
µm. (G) mRNA expression of RAB11FIP4 in 56DIV hCOs showing gene deletion status in
TGD1-3 and aTGD. Statistical analysis by unpaired, two-tailed t-test. (H) RT-qPCR analysis of
microRNA gene expression in CTL hCOs at the time point of highest expression (16DIV).
Statistical analysis by one-way ANOVA; F-ratio / P values reported. MIR4733 was not
expressed in CTL hCOs. Each mRNA expression data point represents one biological replicate
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(hCO), 2-3 hCOs per experimental replicate. (I) Time course analysis of mRNA expression in
16, 35 and 56DIV CTL hCOs for 7 protein-coding genes included in differential gene expression
analysis, illustrating highest transcript expression levels for 6 of the 7 genes at 56DIV. ATAD5
had no change in expression over time. Each time point represents 2 independent experimental
replicates of CTL1 hCOs with each experimental replicate containing 2 biological replicates
(hCOs). Data are shown as the mean ± SEM. (J-N) Representative unprocessed western blots of
CTL and TGD protein expression including (J) COPRS, (K) SUZ12, (L) ATAD5, (M) CRLF3
and (N) UTP6.
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Figure 3.6 | CRLF3 is uniquely disrupted in TGD hCOs and NF1 patients with increased
SRS-2 scores.
(A) 17q11.2 region highlighting the loci uniquely deleted in TGD microdeletions and the CRLF3
gene (red). (B) mRNA and protein expression analysis at 56DIV of protein-coding genes
uniquely deleted in TGD hCOs. Each mRNA data point represents 1 hCO, 3 hCOs per
experimental replicate. Each protein data point represents an independent replicate consisting of
4 pooled hCOs. (C) Western blot and quantification demonstrating reduced CRLF3 protein
levels in TGD relative to CTL and aTGD 56DIV hCOs. Data are shown as the mean ± SEM.
Independent hiPSC lines representing three different CTL or TGD lines (black, CTL1/ TGD1;
white, CTL2/ TGD2; red, CTL3/ TGD3) are shown. (D) Position of the deleterious CRLF3
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c.1166T>C mutation found in 7/17 NF1 patients, with mutational effect predictions using six
methods. (E) NF1 patients with the CRLF3 c.1166T>C mutation (n=7) have higher SRS-2 scores
than those without it (n=10). Box plot indicates median (central line), interquartile range (box)
and minimum and maximum values (whiskers). (C, E) Statistical analysis by unpaired, twotailed t-test.
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Figure 3.7 | CRLF3 sequence conservation, developmental expression, and downstream
signaling.
(A) Amino acid sequence alignments revealed 92.8% conservation in p.Leu389 between human
and 303 vertebrate CRLF3 orthologs. Ten representative orthologs from NCBI’s Eukaryotic
Genome Annotation pipeline are shown, with p.Leu389 outlined in red. (B) Heat map of CRLF3
mRNA expression levels in the human forebrain and hindbrain at different developmental stages,
as reported by the Expression Atlas: Human RNA-seq time-series of the development of seven
major organs. TPM: transcripts per million. (C) Uncropped western immunoblot from Figure
3.8A. (D) Neurofibromin relative expression in CTL, TGD, and shCRLF3 hiPSC-derived NSCs.
Independent hiPSC lines (black, CTL1 / TGD1 / shCRLF3-1; white, CTL2 / TGD2 / shCRLF3-2;
red, CTL3 / TGD3 / shCRLF3-3) are shown. Statistical analysis by unpaired, two-tailed t-test.
(E) Immunoblots and quantitation of neurofibromin expression in different subcellular fractions
(cytoplasm, membrane, nucleus) in shCTL and shCRLF3 NPCs. GAPDH (cytoplasm), Na/K
ATPase (membrane) and human-specific Ku80 (nucleus) were used as loading controls. (F)
Immunoblot and quantitation of CRLF3 expression in NPCs harboring NF1 point mutations,
either conferring <30% reduced (Group 1), or >70% reduced (Group 2) neurofibromin levels,
NPCs harboring homozygous null NF1 mutations (NF1-/-), or non-mutant controls. GAPDH was
used as a loading control. (E-F) Data are expressed as the mean ± SEM. Statistical analysis by
(E) unpaired, two-tailed t-test or (F) one-way ANOVA with Bonferroni post-test correction. ns,
not significant. (G) Representative images of 84DIV shCTL and shCRLF3 hCOs immunolabeled
for deep-layer (TBR1) and upper-layer (SATB2) neurons and quantification of %SATB2+ upperlayer neurons in hCOs at 84DIV. Scale bar: 100 µm. (H) hiPSC-derived NSCs immunolabeled
for NSC markers SOX2, Vimentin, Nestin and PAX6. Scale bar: 50µm. (I) Unprocessed western
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immunoblot from Figure 3.8H. (J) Rac1 activity levels in shCTL and shCRLF3 NSCs. Each
data point represents individual NSC sample. Statistical analysis by unpaired, two-tailed t-test.
(K) RhoA activity in 2DIV TGD and shCRLF3 hCOs with and without 1 µg/mL CN03 RhoA
activator (CN03) treatment for 24 hours. Each data point represents 6 pooled hCOs. Statistical
analysis by two-way ANOVA with Sidak’s multiple comparison test performed comparing
untreated with treated hCOs. All data are shown as the mean ± SEM and the P values are shown
above each bar. (L-N) Representative images of (L) NeuroD1+ (green)/ NeuN+ (red) neurons,
(M) cleaved caspase-3+ apoptotic immature neurons and (N) SMI-32+ dendrites in 35DIV CTL,
TGD and shCRLF3 hCOs with and without CN03 treatment. Scale bars: 50 µm.
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Figure 3.8 | Impaired RhoA signaling drives CRLF3-mediated neuronal defects.
(A) Western blot showing reduced CRLF3 protein levels in CTL1 hiPSCs infected with
shCRLF3 constructs relative to shCTL. (B) NSC proliferation (%Ki67+ NSCs) in 16DIV hCOs
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from shCTL and shCRLF3 lines. (C-E) Images and quantification of shCTL and shCRLF3 hCOs
showing (C) increased production of NeuroD1+ (green) neurons and reduced NeuN+ (red)
neurons, (D) increased apoptotic (Cl. casp-3, green) immature (NeuroD1, red) neurons, and (E)
reduced SMI-32+ dendrites in shCRLF3 compared to shCTL hCOs. (C-E) Each data point
represents one hCO, 3-10 hCOs per hiPSC line. Statistical analysis by unpaired, two-tailed t-test.
(F) Principal component analysis showing distinct transcriptional profiles in CTL, TGD, aTGD,
and shCRLF3 NSCs. (G) Enrichment scores of the top 10 gene ontologies (P value ≤ 0.01) in
shCRLF3 and TGD relative to CTL and aTGD NSCs. (H) Western blot and quantification of Ncadherin protein levels in CTL, TGD, and shCRLF3 NSCs. n = 3 biological replicates per
genotype. Statistical analysis by one-way ANOVA with Dunnett’s multiple comparisons test. (I)
Rac1 and (J-K) RhoA activity levels in (I-J) CTL and TGD or (K) shCTL and shCRLF3 NSCs.
(I-K) Each data point represents an independently generated biological replicate, 3 biological
replicates per genotype. Statistical analysis by unpaired, two-tailed t-test. (L-O) Quantitation of
(L) NeuroD1+ neurons, (M) NeuN+ neurons, (N) cl. caspase-3+ apoptotic immature neurons and
(O) SMI-32+ immunopositive dendrites in 35DIV TGD and shCRLF3 hCOs with and without
CN03 treatment relative to control hCOs. Data are represented as fold-change relative to
controls. Each data point represents one hCO, 2-6 hCOs per experimental replicate, 3-5
experimental replicates per genotype. (A-O) All data are shown as the mean ± SEM.
Independent hiPSC lines representing (A-E) four different shCTL or shCRLF3 lines (black,
shCTL1 / shCRLF3-1; white, shCTL2 / shCRLF3-2; red, shCTL3 / shCRLF3-3; yellow, shCTL4
/ shCRLF3-4), (H, L-O) three different CTL, TGD or shCRLF3 lines (black, CTL1 / TGD1 /
shCRLF3-1; white CTL2 / TGD2 / shCRLF3-2; red, CTL3 / TGD3 / shCRLF3-3), or (I, J) two
different clones for each line (black, clone 1; grey, clone 2) are shown. Scale bars: 50 µm.
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Table 3.1 | Patient-derived CTL1-3, TGD1-3 and aTGD (atypical TGD) hiPSC lines and
isogenic hiPSC lines CRISPR/Cas9-engineered to harbor NF1 patient NF1 gene mutations.

Genotype

Sex

Age (years)

Specimen source

No.
clones

CTL1a

Male

Fetal

Skin biopsy

2

CTL2b

Male

27

Skin biopsy

1

c

CTL3

Male

41

Skin biopsy

1

TGD1

Male

44

Skin biopsy

2

TGD2

Male

6

Urine

2

TGD3

Male

11

Blood

3

aTGD

Female

16

Blood

3

NF1 patient mutation

Protein level

Mutation Type

No.
clones

c.1149C>A

p.Cys383X

Nonsense

2

c.1185+1G>A

p.Asn355_Lys395del

Splice site

2

c.3431-32_dupGT

p.Thr1145Val_FS

Frameshift

2

c.5425C>T

p.Arg1809Cys

Missense

2

Nonsense

1

c.6619C>T
p.Gln2207X
BJFF.6 commercially available
b
Dr. Matthew B. Harms (WUSM)
c
Dr. Fumihiko Urano (WUSM)
a
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Table 3.2 | Human genomic DNA whole-exome sequencing.
Patient ID

SRS-2

Age (years)

Sex

CRLF3-mutation

NF1-mutation

OtB3317

81

10

M

c.1166T>C

c.5305C>T

OtC6610

48

11

F

c.3137_3138delCA

OtB3335

64

11

M

c.1756_1759delACTA

OtB3325

45

11

F

c.3888T>G

OtC6607

70

11

F

c.3449C>T

OtB3313

98

13

M

OtC6614

48

13

M

OtC6612

50

13

M

c.1166T>C

c.910C>T

OtB3333

91

13

M

c.1166T>C

c.204+1G>T

OtB3326

54

15

F

c.1166T>C

c.2125T>C

OtB3321

88

15

M

OtB3312

98

15

M

OtC6619

46

16

F

c.4006C>T

OtC6615

76

16

M

c.205-19T>A

OtB3319

74

16

F

OtB3323

56

17

M

c.1885G>A

OtB3336

46

18

M

c.3520C>T

c.1166T>C

c.7255_7256delCT
c.2965G>T

c.6855C>A
c.1166T>C

c.1166T>C

89

c.4514delG

c.4985G>A

Table 3.3 | Differentially expressed gene list filtered for non-significant genes in the
comparison of TGD vs shCRLF3 samples.
Gene symbol
KCP
SPN
THSD7A
MMP23B
ACOT11
ASCL1
DACT1
LDHAP4
ADGRE5
RUBCNL
NEFM
EPB41L4A
TENM2
MDGA2
CAMK4
SORBS2
ATCAY
PTX3
MANEAL
ITGB8
DCLK2
SYT5
SYP
RASGRP1
MSI1
CRABP1
FCHO1
ECEL1
PLEKHA7
ULBP1
MMRN1

P value
(TGD vs. shCRLF3)
0.1073
0.2332
0.0109
0.0177
0.0456
0.9106
0.0700
0.7063
0.7043
0.8635
0.5160
0.9420
0.2461
0.1567
0.5252
0.0812
0.1408
0.0732
0.0455
0.0134
0.0091
0.0236
0.0102
0.0241
0.0047
0.0052
0.0056
0.0114
0.0097
0.0051
0.0103

FDR step up
(TGD vs. shCRLF3)
0.1689
0.3201
0.0248
0.0373
0.0826
0.9346
0.1184
0.7715
0.7696
0.8992
0.6030
0.9570
0.3342
0.2308
0.6119
0.1341
0.2112
0.1229
0.0825
0.0296
0.0214
0.0474
0.0234
0.0481
0.0121
0.0134
0.0142
0.0257
0.0225
0.0131
0.0237
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Fold change
(TGD vs. shCRLF3)
2.99
2.90
2.84
2.67
2.25
1.82
1.75
1.29
1.25
1.20
1.13
-1.09
-1.27
-1.27
-1.31
-1.64
-1.69
-1.72
-1.78
-1.86
-1.91
-2.25
-2.25
-2.58
-2.58
-2.82
-2.85
-2.90
-3.02
-3.43
-3.89
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Table 3.4 | Summary of experimental samples, replicates and statistical tests used.

Table 3.5 | Key resources table.
REAGENT or RESOURCE
Antibodies
Mouse monoclonal anti-SOX2

SOURCE

IDENTIFIER

Cell Signaling Technology

Rabbit monoclonal anti-SOX2

Abcam

Rabbit monoclonal anti-Oct-4A

Cell Signaling Technology

Rabbit polyclonal anti-Nanog

Cell Signaling Technology

Mouse monoclonal anti-SMI-32

Biolegend

Mouse monoclonal anti-SMI-312

Biolegend

Rabbit monoclonal anti-NeuroD1
Mouse monoclonal anti-NeuroD1

Abcam
Abcam

Mouse monoclonal anti-NeuN

Millipore

Mouse monoclonal anti-Ki-67

BD Biosciences

Mouse monoclonal anti-MAP2 [HM-2]

Abcam

Rabbit monoclonal anti-Cleaved Caspase-3
(Asp175) (5A1E)
Rabbit polyclonal anti-active Caspase-3

Cell Signaling Technology

Goat anti-Rabbit IgG (H+L) Secondary
Antibody, Alexa Fluor 488
Goat Anti-Mouse IgG (H+L) Secondary
Antibody, Alexa Fluor 488
Goat Anti-Rabbit IgG (H+L) Secondary
Antibody, Alexa Fluor 568
Goat Anti-Mouse IgG (H+L) Secondary
Antibody, Alexa Fluor 568
Rabbit polyclonal anti-SUZ12

Thermo Fisher Scientific

Rabbit polyclonal anti-COPRS
Rabbit polyclonal anti-CRLF3

Novus Biologicals
Sigma-Aldrich

Rabbit polyclonal anti-ATAD5

Lifespan Biosciences

Rabbit polyclonal anti-UTP6

Proteintech

Mouse monoclonal anti-GAPDH [6C5]

Abcam

Cat# 4900, RRID:
AB_10560516
Cat# ab92494, RRID:
AB_10585428
Cat# 2840, RRID:
AB_2167691
Cat# 3580, RRID:
AB_2150399
Cat# 801701, RRID:
AB_2564642
Cat# 837904, RRID:
AB_2566782
Cat# ab205300
Cat# ab60704, RRID:
AB_943491
Cat# MAB377, RRID:
AB_2298772
Cat# 556003, RRID:
AB_396287
Cat# ab11267, RRID:
AB_297885
Cat# 9664, RRID:
AB_2070042
Cat# AF835, RRID:
AB_2243952
Cat# A-11034, RRID:
AB_2576217
Cat# A-11029, RRID:
AB_138404
Cat# A-11011, RRID:
AB_143157
Cat# A-11004, RRID:
AB_2534072
Cat# ab12073, RRID:
AB_442939
Cat# NBP2-30884
Cat# HPA007596, RRID:
AB_1847241
Cat# LS-C19118-100,
RRID: AB_1569353
Cat# 17671-1-AP, RRID:
AB_2214465
Cat# ab8245, RRID:
AB_2107448

R&D systems

Thermo Fisher Scientific
Thermo Fisher Scientific
Thermo Fisher Scientific
Abcam
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IRDye 680RD Goat anti-Rabbit IgG
antibody
IRDye 800CW Goat anti-Mouse IgG
antibody
Rabbit monoclonal anti-PAX6

LI-COR Biosciences

Mouse monoclonal anti-OTX2

Thermo Fisher Scientific

Rabbit polyclonal anti-EN1

Thermo Fisher Scientific

Mouse monoclonal anti-GBX2
Rabbit monoclonal anti-TBR1

Lifespan Biosciences
Abcam

Mouse monoclonal anti-SATB2

Abcam

Rabbit polyclonal anti-N-cadherin

Abcam

Mouse monoclonal anti-Neurofibromin
Rabbit polyclonal anti-Nestin

Manuscript in preparation
Abcam

Rabbit monoclonal anti-Vimentin

Cell Signaling Technology

Rabbit monoclonal Anti-Vinculin

Abcam

LI-COR Biosciences
Abcam

Mouse monoclonal anti-neurofibromin
proprietary
Bacterial and Virus Strains
CRLF3 shRNA lentiviral particles
Santa Cruz Biotechnology
Control shRNA lentiviral particles
Santa Cruz Biotechnology
CRLF3-Human shRNA lentiviral particles
OriGene Technologies
(4 unique 29mer target-specific shRNA, 1
scramble control)
Control Lenti particles, scrambled shRNA
OriGene Technologies
Biological Samples
N/A
Chemicals, Peptides, and Recombinant Proteins
Matrigel® Basement Membrane Matrix
Corning
mTeSR™ Plus
STEMCELL Technologies
ReLeSR™
STEMCELL technologies
STEMdiff™ Neural Induction Medium
STEMCELL technologies
Recombinant Human FGF-basic (154 a.a.)
PeproTech
Y27632 RHO/ROCK pathway inhibitor
STEMCELL technologies
Gibco™ B-27 Plus Supplement (50X)
Thermo Fisher Scientific
Gibco™ Neurobasal™ Medium
Thermo Fisher Scientific
Gibco™ DMEM/F-12, HEPES
Thermo Fisher Scientific
Gibco™ N-2 Supplement (100X)
Thermo Fisher Scientific
Human recombinant insulin
Sigma-Aldrich
Gibco™ Penicillin-Streptomycin (5,000
Thermo Fisher Scientific
U/mL)
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Cat# 926-68071, RRID:
AB_10956166
Cat# 925-32210, RRID:
AB_2687825
Cat# ab19504, RRID:
RRID:AB_2750924
Cat# MA5-15854,
RRID:AB_11155193
Cat# PA5-14149,
RRID:AB_2231168
Cat# LS-C197281, NA
Cat# ab31940,
RRID:AB_2200219
Cat# ab51502,
RRID:AB_882455
Cat# ab18203,
RRID:AB_444317
N/A
Cat# ab92391,
RRID:AB_10561437
Cat# 5741,
RRID:AB_10695459
Cat# ab129002
RRID:AB_11144129
n/a
Cat# sc-94066-V
Cat# sc-108080
Cat# TL305215V

Cat# TR30021V

Cat# 354234
Cat# 05825
Cat# 05873
Cat# 05835
Cat# 100-18B
Cat# 72307
Cat# A3582801
Cat# 21-103-049
Cat# 11330057
Cat# 17502001
Cat# I2643-25MG
Cat# 15070063

RIPA Lysis and Extraction Buffer
Gibco™ MEM Non-Essential Amino Acids
Solution (100X)
Gibco™ GlutaMax™ Supplement
2-Mercaptoethanol
Recombinant Human Erythropoietin/ EPO
(Tissue Culture Grade)
Triton™ X-100
Shandon™ Immu-Mount™
Tissue-Tek® O.C.T. Compound, Sakura®
Finetek
Hoechst 33258, Pentahydrate (bisBenzimide)
Pan-RAS-IN-1
4x Laemmli Sample Buffer
Aprotinin, serine protease inhibitor
Leupeptin
PMSF
Puromycin
Gibco™ Goat serum
Poly-L-Ornithine Solution (0.01%)
CellAdhere™ Laminin-521
SB 431542
Compound E
Dorsomorphin
Recombinant Human LIF
Accutase® Cell Detachment Solution
RhoA activator CN03A
Recombinant Human/Murine/Rat BDNF
Recombinant Human IGF-I
Human Recombinant GDNF
Dibutyryl-cAMP, sodium salt 250mg
Critical Commercial Assays
Click-iT™ EdU Cell Proliferation Kit for
Imaging, Alexa Fluor™ 488 dye
In Situ Cell Death Detection Kit,
Fluorescein
Ras Activation ELISA, Colorimetric
RNeasy Mini Kit
Applied Biosystems™ High-Capacity
cDNA Reverse Transcription Kit with
RNase Inhibitor
Applied Biosystems™ TaqMan™ Fast
Advanced Master Mix, no UNG
Pierce™ BCA Protein Assay Kit
RhoA G-LISA Activation Assay,
colorimetric

Thermo Fisher Scientific

Cat# 89900

Thermo Fisher Scientific

Cat# 11140050

Thermo Fisher Scientific
Sigma-Aldrich

Cat# 35050061
Cat# M6250

R&D Systems

Cat# 287-TC-500

Sigma-Aldrich
Thermo Fisher Scientific
Electron Microscopy
Sciences

Cat# X100
Cat# 9990402

Thermo Fisher Scientific

Cat# H3569

MedChemExpress
Bio-Rad
Abcam
Sigma-Aldrich
Sigma-Aldrich
STEMCELL Technologies
Thermo Fisher Scientific
Sigma-Aldrich
STEMCELL Technologies
Tocris
STEMCELL Technologies
Abcam
PeproTech
Fisher Scientific
Cytoskeleton
PeproTech
PeproTech
STEMCELL Technologies
PeproTech

Cat# HY-101295
Cat# 1610747
Cat# ab146286
Cat# L2884
Cat# 10837091001
Cat# 73342
Cat# 16210064
Cat# A-004-C
Cat# 77003
Cat# 1614
Cat# 73952
Cat# ab120843
Cat# 300-05
Cat# MT25058CI
Cat# NC0272107
Cat# 450-02
Cat# 100-11
Cat# 78058
Cat# 1698950

Thermo Fisher Scientific

Cat# C10337

Sigma-Aldrich

Cat# 11684795910

Cell Biolabs
Qiagen
Thermo Fisher Scientific

Cat# STA-440
Cat# 74104
Cat# 4374966

Thermo Fisher Scientific

Cat# A44359

Thermo Fisher Scientific
Cytoskeleton

Cat# 23225
Cat# BK124
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Cat# 4583

Rac1 G-LISA Activation Assay,
colorimetric
Deposited Data
Whole exome sequencing data
RNA sequencing data
Human RNA-seq time-series of the
development of seven major organs
Experimental Models: Cell Lines
BJFF.6 (CTL1) hiPSCs
TGD1 hiPSCs
TGD2 hiPSCs
TGD3 hiPSCs
aTGD hiPSCs
shCTL1 hiPSCs
shCTL2 hiPSCs
shCTL3 hiPSCs
shCTL4 hiPSCs
shCRLF3-1 hiPSCs
shCRLF3-2 hiPSCs
shCRLF3-3 hiPSCs
shCRLF3-4 hiPSCs
c.1149C>A NF1-mutant hiPSCs
c.1185+1G>A NF1-mutant hiPSCs
c.3431-32_dupGT NF1-mutant hiPSCs
c.5425C>T NF1-mutant hiPSCs
c.6619C>T NF1-mutant hiPSCs
CTL2 hiPSCs

CTL3 hiPSCs

Experimental Models: Organisms/Strains
N/A
Oligonucleotides
Human CRLF3 - TaqMan® Gene
Expression Assay FAM-MGB
Human ATAD5 TaqMan® Gene Expression
Assay FAM-MGB
Human TEFM TaqMan® Gene Expression
Assay FAM-MGB
Human ADAP2 TaqMan® Gene Expression
Assay FAM-MGB
Human COPRS TaqMan® Gene Expression
Assay FAM-MGB

Cytoskeleton

Cat# BK128

This paper
This paper
Expression Atlas

GEO accession # pending
GEO accession # pending
https://www.ebi.ac.uk/gxa
/experiments/E-MTAB6814/Results

GeiC – Washington
University
This paper
This paper
This paper
This paper
This paper
This paper
This paper
This paper
This paper
This paper
This paper
This paper
(Anastasaki et al., 2020)
(Anastasaki et al., 2020)
(Anastasaki et al., 2020)
(Anastasaki et al., 2020)
(Anastasaki et al., 2020)
GeiC – Washington
University (Dr. Matthew B.
Harms)
GeiC – Washington
University (Dr. Fumihiko
Urano)

RRID: CVCL_VU02

N/A

N/A

Thermo Fisher Scientific

Hs00367579_m1

Thermo Fisher Scientific

Hs00227495_m1

Thermo Fisher Scientific

Hs00895248_m1

Thermo Fisher Scientific

Hs01106939_m1

Thermo Fisher Scientific

Hs01047650_m1
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N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A

N/A

Human UTP6 TaqMan® Gene Expression
Assay FAM-MGB
Human SUZ12 TaqMan® Gene Expression
Assay FAM-MGB
Human LRRC37B TaqMan® Gene
Expression Assay FAM-MGB
Human MIR193A TaqMan® Gene
Expression Assay FAM-MGB
Human MIR365B TaqMan® Gene
Expression Assay FAM-MGB
Human MIR4725 TaqMan® Gene
Expression Assay FAM-MGB
Human MIR4733 TaqMan® Gene
Expression Assay FAM-MGB
Human GAPDH TaqMan® Gene
Expression Assay FAM-MGB
Recombinant DNA
N/A
Software and Algorithms
Samtools 1.4.1
SnpEff
Combined Annotation Dependent Depletion
(CADD)
SIFT
PolyPhen: Polymorphism Phenotyping
Likelihood ratio test (LRT)
GERP++
Fathmm
Leica Application Suite X software

ImageJ/ Fiji v1.8
Bio-Rad CFX Manager 3.1

LI-COR Image Studio Software v5.2

COBALT: Constraint-based Multiple
Alignment Tool

Thermo Fisher Scientific

Hs00251161_m1

Thermo Fisher Scientific

Hs00248742_m1

Thermo Fisher Scientific

Hs03045845_m1

Thermo Fisher Scientific

Hs04273253_s1

Thermo Fisher Scientific

Hs04231549_s1

Thermo Fisher Scientific

Hs06637953_s1

Thermo Fisher Scientific

Hs04274676_s1

Thermo Fisher Scientific

Hs02786624_g1

N/A

N/A

http://samtools.sourceforge.ne
t/
http://snpeff.sourceforge.net/
https://cadd.gs.washington.ed
u/
http://sift.bii.a-star.edu.sg/
http://genetics.bwh.harvard.e
du/pph2/
http://www.genetics.wustl.ed
u/jflab/lrt_query.html
http://mendel.stanford.edu/Si
dowLab/downloads/gerp/
http://fathmm.biocompute.org
.uk/fathmm-xf/about.html
https://www.bio-rad.com/enus/sku/1845000-cfx-managersoftware?ID=1845000
http://fiji.sc
https://www.bio-rad.com/enus/sku/1845000-cfx-managersoftware?ID=1845000
https://www.licor.com/bio/pr
oducts/software/image_studio
/?gclid=EAIaIQobChMIrv7s2
6ug1wIVQUCGCh1kvQgLE
AAYASAAEgLcYPD_BwE
http://www.ncbi.nlm.nih.gov/
tools/cobalt/cobalt.cgi?link_l
oc=BlastHomeAd

RRID: SCR_002105
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RRID: SCR_005191
RRID: SCR_018393
RRID: SCR_012813
RRID: SCR_013189
N/A
RRID: SCR_000563
N/A
RRID: SCR_013673

RRID: SCR_002285
N/A

RRID: SCR_015795

RRID: SCR_004152

GraphPad Prism 8
Adobe Illustrator 2020
Adobe Photoshop 2020
Jalview
Samtools
bcl2fastq

STAR version 2.7.3a
Ensembl
DESeq2

Partek Flow software, version 9.0.20
Gene Ontology enrichment
Other
Corning® Costar® Ultra-Low Attachment
96 well round bottom plate
Corning® Costar® Ultra-Low Attachment
24 well plate
25cm2 Tissue Culture Flask - Vent Cap,
Sterile
6 Well Tissue Culture Plate, Sterile

http://www.graphpad.com/
http://www.adobe.com/produ
cts/illustrator.html
https://www.adobe.com/prod
ucts/photoshop.html
http://www.jalview.org/
http://samtools.sourceforge.ne
t/
https://support.illumina.com/s
equencing/sequencing_softwa
re/bcl2fastq-conversionsoftware.html
https://github.com/alexdobin/
STAR
http://www.ensembl.org/
https://bioconductor.org/pack
ages/release/bioc/html/DESeq
2.html
https://www.partek.com/?q=p
artekgs
http://geneontology.org/

RRID: SCR_002798
RRID: SCR_010279

Sigma-Aldrich

Cat# CLS7007

Sigma-Aldrich

Cat# CLS3473

CELLTREAT

Cat# 229331

Celltreat

Cat# 229106
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RRID: SCR_014199
RRID: SCR_006459
RRID:SCR_002105
RRID:SCR_015058

RRID:SCR_015899
RRID:SCR_002344
RRID:SCR_015687

RRID:SCR_011860
RRID:SCR_002811

3.7 Discussion
The successful deployment of the hCO platform to identify the cellular and molecular etiologies
for human 17q11.2 microdeletion-related neurodevelopmental abnormalities raises several
important points. First, it adds CRLF3 to the growing list of genes contained within the NF1TGD locus that could contribute to specific clinical phenotypes observed not only in patients
with NF1, but also in the general population. For example, mutations in RNF135 have been
reported in patients with autism (Tastet et al., 2015) and in families with dysmorphic facial
features and learning disabilities (Douglas et al., 2007). Biallelic loss of SUZ12 is frequently
observed in malignant peripheral nerve sheath tumors (MPNSTs) (Lee et al., 2014; Zhang et al.,
2014), while ADAP2 is required for normal cardiac morphogenesis (Venturin et al., 2014)
relevant to cardiovascular malformations observed in 17q11.2 microdeletion patients (Venturin
et al., 2004). Further investigation into the roles of other deleted genes within this interval may
provide new insights relevant to the diagnosis and treatment of human disease. Second, using a
combination of lentiviral CRLF3 genetic silencing and pharmacologic rescue of RhoA activity
experiments (CN03 treatments), we establish that CRLF3 regulates human neurogenesis, neuron
survival, and dendritic development through RhoA activation, extending prior studies on the role
of RhoA signaling in murine neuron maturation relevant to neurodevelopment and cognition
(Richter et al., 2019). Third, the provocative early-phase clinical analyses suggest that CRLF3
mutation might identify a high-risk group of NF1 patients more likely to harbor an increased
autism trait burden. While CRLF3 has not been previously implicated as an autism risk gene
(Abrahams et al., 2013; Banerjee-Basu and Packer, 2010), it constitutes a potential therapeutic
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target and a risk assessment tool in future studies involving larger numbers of individuals, with a
focus on its sensitivity and specificity for predicting ASD symptomatology in children with NF1.

Limitations of the Study
While we show that CRLF3 reduction accounts for the impaired neuronal maturation and
dendritic outgrowth in NF1-TGD hCOs, further work will be required to establish a link between
NF1-TGD dendritic dysfunction and autism. Additionally, analysis of an in vivo model would be
required to validate the translatability of these results. Similarly, as aTGD mutations are quite
rare, additional studies should focus on the neuronal function in this subset of TGD patients.
Lastly, with the availability of reliable antibodies that recognize the proteins encoded by other
genes in the microdeletion locus and CRLF3 expression constructs, future studies could explore
the relationship between these deleted genes and brain development.
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Chapter 4: Conclusions and Future
Directions
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4.1 Preface
Parts of this chapter are adapted from the following manuscript:
Wegscheid, M.L., Anastasaki, C. & Gutmann, D.H. Human stem cell modeling in
neurofibromatosis type 1 (NF1). Experimental Neurology 299, 270-280 (2018).

Author contributions for the citation above:
M.L.W. and D.H.G. wrote the paper. M.L.W. and C.A. made the figures.
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4.2 Summary of findings
The implementation of precision medicine strategies requires the identification of the factors that
underlie individual disease risk and predict clinical outcome, as well as the development of
human cellular platforms for therapeutic evaluation. This challenge is exemplified by NF1, a
common neurogenetic single-gene disorder in which affected individuals exhibit a wide range of
medical problems (Jett and Friedman, 2010). Based on emerging population-based genotypephenotype association studies in NF1 (Anastasaki et al., 2017; Koczkowska et al., 2018b;
Mautner et al., 2010; Morris et al., 2016a; Morris and Gutmann, 2018; Pinna et al., 2015; Sharif
et al., 2011; Trevisson et al., 2019; Upadhyaya et al., 2007), we hypothesized that the germline
NF1 gene mutation represents one clinically actionable risk factor for NF1-associated
symptomatology. The experiments described in this dissertation critically evaluated this
hypothesis by investigating the effects of different NF1 mutations on human neurodevelopment
using a collection of isogenic and non-isogenic hiPSC-derived CNS cells and human cerebral
organoids (hCOs) harboring patient-derived NF1 germline gene mutations.

The hypothesis that was raised in Chapter 1 was addressed in Chapter 2 of this dissertation and is
summarized in Figure 4.1. In Chapter 2, we analyzed an isogenic series of CRISPR/Cas9engineered hiPSCs harboring seven different intragenic NF1 patient germline NF1 gene
mutations, as well as patient-derived hiPSCs and Nf1-mutant mice bearing the same mutations.
Importantly, unlike previous studies, the use of an isogenic series of hiPSCs eliminated other
contributing factors, such as sex and background genomic variation, and permitted a direct
examination of the effects of different NF1 gene mutations. These experiments revealed both
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common and differential effects of distinct NF1 germline gene mutations on CNS cells and
tissues.

Figure 4.1 | Experimental conclusions from Chapter 2. hiPSC-derived NF1-mutant NPCs
and hCOs revealed both common and differential effects of distinct NF1 gene mutations on
human CNS cells and tissues.
Consistent with numerous reports in Nf1-mutant mouse models describing NF1/RAS-mediated
control of cell proliferation (Hegedus et al., 2007; Kaul et al., 2015; Lee et al., 2010; Wang et al.,
2012), all isogenic NF1-mutant 2D NPCs and astrocytes exhibited an increase in RAS activity,
as well as increased cell proliferation. Patient-derived NPCs, as well as to whole-brain lysates
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from genetically engineered mice harboring analogous germline Nf1 gene mutations, were also
confirmed to have increased RAS activity. Similarly, isogenic and patient-derived NF1-mutant
hCOs exhibited increased whole-organoid RAS activity and production of astrocytes, illustrating
that all heterozygous NF1 mutations increase RAS activity and RAS-regulated cell proliferation
in human and murine CNS cells. Experiments leveraging 2D hiPSC-derived GABAergic neurons
also revealed a shared abnormality of increased GABA levels, consistent with previous studies
describing increased GABAergic tone in Nf1-mutant (Nf1+/−) mice (Costa et al., 2002; Cui et al.,
2008).

In contrast, we observed differential effects of NF1 germline gene mutations on 2D NPC
dopamine (DA) levels, as well as NPC proliferation, apoptosis and neuronal differentiation in 3D
hCOs. In contrast to Nf1+/- mice exhibiting 50% reductions in hippocampal DA levels
(Anastasaki et al., 2015), one group of NF1-mutant NPCs (c.1149C>A; c.2041C>T;
c.6619C>T), had >70% reduction in dopamine levels compared to controls, whereas another
group of NF1-mutant NPCs (c.1185+1G>A; c.3431-32_dupGT, c.5425C>T, and c.6513T>A)
had <40% reduction in DA levels. This finding was recapitulated in patient-derived 2D NPCs, as
well as Nf1-mutant genetically engineered mouse brain lysates harboring analogous mutations. In
isogenic and patient-derived hiPSC-hCOs, one group of NF1 mutants (c.1185+1G>A;
c.5425C>T; c.6619C>T) exhibited increased NPC proliferation and apoptosis, while the other
group of NF1 mutants (c.1149C>A; c.3431-32_dupGT) had normal NPC proliferation, but
reduced NPC apoptosis. In addition, this latter group of NF1 mutants had delayed production of
immature neurons. The proof-of-concept experiments described in Chapter 2 clearly demonstrate
that distinct NF1 mutations have differential effects on human CNS cells and tissues. In
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combination with compelling population-based genotype-phenotype associations, these
experiments (1) suggest that the germline NF1 gene mutation is one of the factors that underlies
clinical heterogeneity in patients with NF1 and (2) highlight the significance of employing
preclinical models with different patient germline mutations to better represent the unique
pathologies in patients. In addition, these findings support the existence of RAS-independent
neurofibromin functions, as the observed differences in neuronal differentiation in cerebral
organoids and NPC DA levels do not correlate with RAS activity levels. Lastly, the observation
that all NF1-mutant 2D NPCs exhibited increased proliferation, but only a subset of NF1-mutant
hCOs exhibited increased NPC proliferation, attests to the critical role of heterogenous cell-cell
interactions (e.g., differentiating neurons, astrocytes and NPCs) in dictating phenotypic
outcomes. This notion is further supported by previously reported cell-autonomous and non-cellautonomous (stromal) effects of distinct Nf1 gene mutations on astrocyte proliferation in
genetically engineered murine models of optic pathway glioma (Kaul et al., 2015). Future studies
aimed at dissecting the complex interplay between different cell types relevant to brain
developmental abnormalities and tumorigenesis in personalized NF1 preclinical models will be
instrumental in defining molecular and cellular mechanisms underlying disease heterogeneity.

In Chapter 3, we sought to understand the molecular and cellular etiologies underlying the severe
developmental delays and intellectual disability seen in children with a specific type of NF1
mutation involving a heterozygous microdeletion of the NF1 gene and several contiguous genes
(1.4 Mb NF1-total gene deletion [NF1-TGD]). For these studies, we analyzed hCOs derived
from three neurologically normal control individuals and three individuals harboring a 1.4 Mb
NF1-TGD. The experimental conclusions from Chapter 3 are summarized in Figure 4.2.
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Figure 4.2 | Experimental conclusions from Chapter 3. Patient-derived hiPSC-hCOs
harboring a 1.4 Mb NF1-TGD revealed RAS-dependent roles for the NF1 gene in human NPC
proliferation, as well as critical roles for CRLF3-dependent RhoA activation in neuronal
survival, differentiation, and maturation.

First, our experiments revealed that total deletion of one copy of the NF1 gene increases NPC
proliferation through RAS inactivation in hCOs. This finding is consistent with results from one
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group of NF1-mutant hCOs harboring c.1185+1G>A, c.5425C>T, and c.6619C>T intragenic
NF1 mutations. Second, we identified neuronal defects (delayed neuronal differentiation,
reduced immature neuron survival and markedly impaired dendrite maturation) in the 1.4 Mb
NF1-TGD hCOs that were not found in hCOs harboring NF1 intragenic mutations or a 0.6-0.9
Mb atypical deletion. Third, we discovered impaired cytokine receptor-like factor 3 (CRLF3)mediated RhoA signaling as the etiologic mechanism underlying the 1.4 Mb NF1-TGD defects
in neuronal differentiation, survival and dendrite maturation. Lastly, we demonstrated a higher
autistic trait burden in NF1 patients harboring a deleterious germline mutation in the CRLF3
gene (c.1166T>C, p.Leu389Pro). Collectively, these experiments revealed a causative gene
within the NF1-TGD locus responsible for the profound neurodevelopmental defects in NF1TGD hCOs and autistic trait burden in children with NF1.

4.3 Future directions
The experiments herein have demonstrated that distinct NF1 gene mutations exert differential
effects on human CNS cells and tissues. These proof-of-concept studies serve as a foundation for
future studies aimed at (1) investigating the cellular and physiological consequences of specific
germline patient mutations relevant to NF1 disease pathogenesis and (2) dissecting the molecular
mechanisms underlying NF1-associated phenotypes. Mechanistic etiologies underlying the
observed neurogenic abnormalities in intragenic and NF1-TGD NF1-mutant hCOs from Chapter
2 and 3 are discussed in section 4.3.1. The potential applications of this NF1-mutant iPSC-hCO
platform to model additional NF1-associated pathologies is discussed in section 4.3.2.
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4.3.1 Mechanistic etiologies
RAS signaling pathway responsible for NPC hyperproliferation
To define the RAS downstream signaling pathway responsible for driving increased NPC
proliferation in NF1-TGD and several intragenic NF1-mutant hCOs, we surveyed RAS effectors
that have been previously implicated in the regulation of CNS cell proliferation and
differentiation in murine models of NF1 (ERK, AKT, S6, cyclic AMP) (Chen et al., 2015;
Hegedus et al., 2007; Kaul et al., 2015; Lee et al., 2010; Sanchez-Ortiz et al., 2014; Wang et al.,
2012). There was no difference in intracellular levels of cAMP between NF1-TGD and control
(CTL) hCOs at 16DIV (Figure 4.3A). Furthermore, preliminary western blotting results revealed
inconsistent changes in ERK, AKT or S6 phosphorylation between genotypes (Figure 4.3B-E).
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Figure 4.3 | Analysis of RAS downstream effectors in TGD hiPSC-hCOs.
(A) cAMP levels in TGD compared to CTL 16DIV hCOs. Independent hiPSC lines
representing three different CTL lines (black, CTL1; white, CTL2; red, CTL3) and three
different TGD lines (black, TGD1; white, TGD2; red, TGD3) are shown. Each data point
represents 3 pooled organoids. (B-D) Representative Western blots and (E) quantification
of pAKTS473, pERK1/2T202/T204 and pS6S240/244 levels in CTL and 1.4 Mb NF1-TGD 16DIV
hCOs. GAPDH was used as a total protein loading control. N represents the number of
independent organoid lysates analyzed. Statistical analysis by unpaired, two-tailed t-test.

One possible explanation for the highly variable results in phospho-protein activation in iPSChCOs could be the heterogenous composition of the organoid cultures. While spontaneous
unguided hCO differentiation offers the unique opportunity to model the evolution of selforganizing cerebral tissues, each organoid generated by this protocol contains variable numbers
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of NPC-containing zones. It is possible that the variability in hCO NPC zone numbers per tissue
could affect the measured whole organoid effector activation. One strategy to overcome this
would be to generate hCOs containing a single ventricle-like zone using defining patterning
molecules to improve reproducibility (Lee et al., 2016). Alternatively, hCO-NPCs could be
isolated using fluorescent activated cell sorting (FACS) (Janssens et al., 2019), and downstream
effector engagement assayed on a pure population of hCO-derived NPCs. We have previously
attempted to measure effector activation in 2D hiPSC-NPCs, but had similarly variable results in
ERK, AKT and S6 phosphorylation across replicates. Further optimization will be required to
assess RAS downstream effector activation in 2D NPCs and 3D hCOs. Ultimately, future
experiments aimed at understanding (1) how NF1/RAS downstream signaling pathway
engagement dictates cellular responses and (2) how those outputs can be contextually modified
(genetic, cellular and tissue levels) (Smithson et al., 2016), will lead to the design of more
effective, individualized therapies for NF1-associated pathologies.

Alternative neurofibromin-binding partners
The fact that the observed differences in neuronal differentiation in intragenic NF1-mutant hCOs
and 2D NPC DA levels do not correlate with RAS activation supports the existence of non-RASmediated neurofibromin functions. Putative neurofibromin binding partners include proteins
important for neuronal differentiation, such as syndecans (Hsueh et al., 2001), vasolin-containing
protein (Wang et al., 2011), tubulin (Bollag et al., 1993), and serotonin 5-HT6 receptors
(Deraredj Nadim et al., 2016) (Figure 4.4). However, the validation of neurofibromin binding
partners has largely been hindered by a lack of high affinity anti-neurofibromin antibodies. To
overcome this obstacle, the Gutmann Laboratory has generated an endogenous FLAG-tagged
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NF1 allele in both hiPSCs and genetically engineered mice to effectively immunoprecipitate
neuron-specific neurofibromin binding complexes and investigate these protein-protein
interactions using mass spectrometry. These investigations will be critical to advance our
understanding of how NF1 mutations differentially affect cognition and behavior in children with
NF1.
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Figure 4.4 | Neurofibromin domains and putative binding partners.
Schematic diagram illustrating neurofibromin domains, including a cysteine–serine-rich
domain (CSRD), a tubulin-binding domain (TBD), a GTPase-activating protein-related
domain (GRD), a Sec14 domain, a pleckstrin homology (PH) domain, a carboxy-terminal
domain (CTD), and a syndecan-binding domain (SBD). Positions of the intragenic patientderived NF1 mutations discussed in this dissertation are indicated. Proteins that are believed
to interact with each domain are indicated in the accompanying table. Adapted from (Ratner
and Miller, 2015).
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4.3.2 Prospective directions for hCO modeling of NF1-associated brain
pathologies
Neuronal subtype specification and functional maturation
In this dissertation, we leveraged an iPSC-hCO experimental platform to investigate the effects
of different NF1 mutations on early human brain development, as transcriptome and epigenome
studies have demonstrated that hCOs most closely resemble fetal brain expression signatures
during the first and early second trimester (Camp et al., 2015; Luo et al., 2016; Qian et al.,
2016a; Velasco et al., 2019). However, hiPSC-hCOs can also be leveraged to investigate NF1
mutational effects on mid-gestational neuronal subtype specification and functional maturation.
Preliminary results and alternative approaches to investigating these parameters are discussed
below.

Neurodevelopmental disorders frequently involve neuronal subtype (e.g., excitatory and
inhibitory) imbalances that arise during brain development (Gao and Penzes, 2015). Based on
this observation, we hypothesized that NF1 gene mutations may differentially impair the
specification and functional maturation of excitatory and inhibitory neurons during brain
development. To evaluate the effects of NF1 gene mutations on neuronal subtype specification,
we evaluated the production of glutamatergic (glutaminase+) and GABAergic (GAD67+) neurons
in hCOs using immunohistochemistry at 105 days in vitro (DIV). In contrast to previous reports
describing mature neuronal subtypes and spontaneous synaptic activity in hCOs between 3-6
months in culture (Monzel et al., 2017; Pasca et al., 2015; Qian et al., 2016b; Quadrato et al.,
2017; Trujillo et al., 2019), our preliminary experiments revealed that distinct populations of
glutamatergic and GABAergic neurons did not form 105DIV in NF1-mutant or control cerebral
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organoids. Furthermore, using a Maestro multi-electrode array (MEA) system, we confirmed that
105DIV hCOs did not spontaneously fire action potentials.

Notably, hCO differentiation protocols used in studies describing subtype specification and
functional maturation supplemented cerebral organoid differentiation media with BDNF, GDNF,
L-ascorbic acid, cAMP and TGFβ3 to promote maturation. Based on this observation, we
generated cerebral organoids using a modified protocol to promote neuronal maturation, in
which standard hCO media was supplemented with 200 µM L-ascorbic acid, 500 µM dibutyryl
cAMP, 1 ng/mL TGFβ3, 10 ng/mL BDNF and 10 ng/mL GDNF. Using immunohistochemistry,
we confirmed that distinct neuronal subtypes were produced in cerebral organoids by 105DIV
using this modified protocol (Figure 4.5A). However, >70% of the neurons were still double
positive for GAD67 and glutaminase in controls and NF1-mutants after 105DIV using the
modified protocol, suggesting that subtype specification was incomplete.

In addition, synaptic activity was detected in cerebral organoids after 105DIV in hCOs generated
using the modified maturation protocol (Figure 4.5B). Action potentials and burst activity were
detected in CTL and NF1-mutant hCOs. Network bursting activity, which measures the presence
and functionality of mature neuronal networks, was not detected. Maximum mean firing rates in
CTL and NF1-mutant hCOs were lower than reported averages in the literature for 105DIV hCOs,
(~0.6 Hz compared to reported 2.5 Hz) (Trujillo et al., 2019), and largely derived from only a
handful of active electrodes. In addition, different tissues from the same experimental replicate
frequently exhibited variable activity, with some tissues still having no spontaneous activity.
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Figure 4.5 | hCO neuronal subtype specification and functional maturation.
(A) Representative images of 105DIV cerebral organoids immunolabeled for glutamatergic
neurons (glutaminase, red) and GABAergic neurons (GAD67, green). The insets illustrate
mature GABAergic neurons (GAD67+, glutaminase-), mature glutamatergic neurons
(glutaminase+, GAD67-) and neurons of unspecified subtype (glutaminase+, GAD67+). Scale
bar: 50 µm. (B) A representative image of a spike raster plot illustrating neuronal network
activity over 64 electrodes during a 60-minute recording session in a 105DIV cerebral
organoid. Each individual spike represents an action potential from a neuron. Neuronal
bursting activity is indicated by blue spikes.
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Taken together, these results demonstrate the need to maintain CTL and NF1-mutant hCOs for
longer than 105DIV to achieve neuronal subtype specification and functional maturation, and to
assess for differences in those parameters. Another potentially important difference between our
hCO protocol and many described in the literature involves embedding of 3D tissues in gelatinous
protein matrices (Matrigel). While several hCO protocols do not employ Matrigel embedding
(Anastasaki et al., 2020; Pasca et al., 2015; Trujillo et al., 2019), many protocols do incorporate
extracellular matrices to support the outgrowth of neuroepithelial buds. We spent several months
optimizing cerebral organoid cultures with this Matrigel embedding step. However, ~40% of hCOs
did not survive Matrigel embedding, and the remaining hCOs embedded in Matrigel had highly
heterogenous shapes and sizes across experimental replicates. Further optimization of this
protocol, either by incorporating micro-scaffolds or solubilized Matrigel (Lancaster et al., 2017),
may improve reproducibility of long-term cultures and derivation of cortical tissues with mature
neuronal subtypes.

Methods for MEA
MEA recording was conducted using the Maestro MEA system from Axion BioSystems. A 6well MEA plate (catalog no. M384-TMEA-6W) plate containing 64 platinum microelectrodes
per well, was precoated with polyethyleneimine and 10µg/mL laminin. Cerebral organoids were
placed onto the array at 84DIV and were cultured on the plates for an additional 3 weeks prior to
recording. Measurements were collected 3 hours after medium was changed at 105DIV of
differentiation. The plate was first allowed to rest in the Maestro device for 10 minutes prior to
data collection. Spontaneous activity was recorded using AxIS Software v2.5.2.1, Spontaneous
Neural Configuration (Axion Biosystems) at a sampling rate of 12.5 kHz for 15 minutes at 37°C
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in neuronal maturation media. A Butterworth band pass filter with 200-3000 Hz cutoff frequency
and a threshold of 6 x SD were set to minimize false-positives and missed detections. The Neural
Metric Tool v2.6 (Axion BioSystems) was used to analyze the spike raster plots. Electrodes with
an average of ≥5 spikes/min were defined as active. Bursts were identified in the data recorded
from each individual electrode using an inter-spike interval (ISI) threshold requiring a minimum
number of 5 spikes with a maximum ISI of 100 ms. A minimum of 10 spikes under the same ISI
with a minimum of 25% active electrodes were required for network bursts in the well.

Myelination/ Oligodendrocytes
Another critically important cell type in the developing human brain, amenable to hCO modeling,
is oligodendrocytes. Oligodendrocyte ensheathment of neuronal axons is a prerequisite for
saltatory nerve conduction (Kaplan et al., 1997). Furthermore, oligodendrocytes play a critical role
in providing neurotrophic and metabolic support to neurons (Dougherty et al., 2000; Wilkins et
al., 2003). 60-70% of children with NF1 exhibit white matter abnormalities (enlarged brain white
matter tracts, T2 hyperintensities and altered fractional anisotropy and diffusivity on diffusion
tensor imaging) (Karlsgodt et al., 2012; North, 2000) that could contribute to NF1-associated
neurological abnormalities. While Nf1 gene inactivation in murine models has been shown to result
in increased numbers of oligodendrocyte progenitors (OPCs) (Bennett et al., 2003; Hegedus et al.,
2007), the effects of NF1 gene mutations on oligodendrocyte differentiation and function have not
been assessed. Recently, cerebral organoid cultures (>100DIV) that incorporate factors to promote
OPC survival and oligodendrocyte maturation have been shown to develop OPCs and myelinating
oligodendrocytes (Kim et al., 2019; Madhavan et al., 2018; Marton et al., 2019). These iPSC-hCOs
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could provide a unique experimental platform to investigate the cellular and molecular
consequences of patient NF1 mutations on oligodendrogenesis and myelination.

Microglia
The critical importance of microglia to brain development and homeostasis is underscored by
numerous reports demonstrating that microglia regulate synaptic plasticity through pruning (Liu
et al., 2017; Lui et al., 2016), as well as underlie some of the behavioral and cognitive abilities of
rodents (Acharya et al., 2016; Rice et al., 2015). Studies have shown that mesoderm progenitors
(Quadrato et al., 2017) and microglia (Ormel et al., 2018) develop spontaneously in hCOs
generated without the use of inhibitors or molecular pathway manipulators. Based on these
studies, we hypothesized that microglia were also present in CTL and NF1-mutant hiPSC-hCOs.
Preliminary immunofluorescence experiments in CTL hCOs have revealed that IBA-1+ cells
develop in hCOs by 56DIV; however, the fraction of IBA-1+ cells per organoid and between
replicates was variable. Future experiments should confirm the cellular identity of the IBA-1+
cells in hCOs using additional markers of microglia (e.g., TMEM119, P2RY12 receptor) and
critically evaluate whether the microglia population in control hCOs is representative of what is
found in the normal human brain (0.5-16.6% of all cells) (Mittelbronn et al., 2001). If the
microglia that spontaneously develop in hCOs are not representative of the normal human brain,
future studies could incorporate hiPSC-microglia into cerebral organoids to assess the effects of
microglia on NF1-associated brain pathologies. Advances in iPSC reprogramming now enable
the generation of human microglia-like cells with expression profiles similar to both primary
fetal and adult microglia (Abud et al., 2017; Muffat et al., 2016).
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Brain tumors
Optic pathway gliomas (OPGs) are seen in 15-20% of children with NF1 and are almost never
biopsied as part of routine medical care (Jett and Friedman, 2010). As a result, much of our
understanding of NF1-OPG pathogenesis derives from the use of Nf1 genetically engineered
mouse (GEM) models. Mice heterozygous for a germline Nf1 gene mutation (Gutmann et al.,
1999a), in which somatic Nf1 loss occurs in neuroglial progenitors, develop optic gliomas
(Bajenaru et al., 2002). Importantly, Nf1 loss in neuroglial progenitor cells alone does not result
in gliomagenesis. Tumor formation requires the presence of cells heterozygous for an
inactivating Nf1 gene mutation (Bajenaru et al., 2003). This finding suggests that Nf1+/- stromal
cells are critical for tumor formation and maintenance (Bajenaru et al., 2003). One of these nonneoplastic cell types in these tumors are microglia, immune system-like cells that mature within
the developing brain (Ginhoux et al., 2013). Formal proof for the critical role for microglia in
murine optic glioma formation and maintenance derives from studies in which pharmacologic or
genetic inhibition of microglial function is sufficient to delay tumorigenesis and reduce tumor
proliferation, respectively (Daginakatte and Gutmann, 2007; Pong et al., 2013; Solga et al.,
2015).

While these mouse tumors share many of the histologic and biologic features of their human
counterparts, there are important differences. One difference relates to the level of microglial
enrichment in gliomas, which is much smaller in mice (~10-15%) relative to most human NF1low grade gliomas (35-50%) (Simmons et al., 2011). Future studies using 3D mixed cultures
containing NF1-deficient human neuroglial progenitor cells in combination with heterozygous
NF1-mutant iPSC-stromal cells may reveal new targets for future stroma-directed low-grade
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glioma treatments. In this regard, the Gutmann Laboratory has engineered representative
homozygous NF1-mutant (NF1 null) hiPSC lines. Preliminary experiments have employed
mixed organoids, in which 1-10% of starting cells were NF1 null and 90-99% of starting cells
were heterozygous for a patient NF1 gene mutation, to assess for histological characteristics of
low-grade gliomas (e.g., increased cellularity, increased proliferation, gliogenesis and tissue
disorganization). However, microglia were not assessed in these preliminary co-cultures. Further
optimization of these co-culture platforms will potentially allow for more detailed
characterization of host-specific tumor pathophysiology and could serve as a tractable preclinical
platform for drug development and screening.

4.4 Concluding Remarks
The findings presented in this dissertation advance our understanding of the key determinants
that account for differences between individuals with NF1-associated neurodevelopmental
abnormalities. Collectively, these studies lay the foundation for future preclinical research using
human iPSCs and cerebral organoids for NF1 precision medicine. As the number of NF1 patientderived iPSCs grows, one could envision the creation of an international repository for highthroughput cellular and molecular phenotyping. The use of patient-derived iPSCs, in conjunction
with credentialed small-animal disease models, offers unprecedented opportunities to discover
subgroups of patients most likely to exhibit specific NF1 clinical features or respond to specific
therapies. This “fingerprinting” approach might facilitate the identification of individuals at
greatest risk for specific symptomatology in NF1, as well as the development of personalized
therapeutic strategies.
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